{"title":"Peptide Stacks","description":"\u003cp data-start=\"2205\" data-end=\"2301\"\u003eCurated groupings of research compounds frequently examined together in experimental settings.\u003c\/p\u003e\n\u003cp data-start=\"2308\" data-end=\"2359\"\u003eStacks are bundled for research convenience only.\u003c\/p\u003e\n\u003cp data-start=\"2366\" data-end=\"2416\"\u003eAll products are for laboratory research use only.\u003c\/p\u003e","products":[{"product_id":"semax","title":"Semax","description":"\u003cdiv class=\"wd-page-content main-page-wrapper\"\u003e\u003cmain role=\"main\" class=\"wd-content-layout content-layout-wrapper wd-builder-off\" id=\"main-content\"\u003e\n\u003cdiv role=\"main\" id=\"content\" class=\"site-content col-lg-12\"\u003e\n\u003cdiv class=\"container\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"content-area col-sm-12\"\u003e\n\u003cdiv class=\"elementor elementor-6554\" data-elementor-id=\"6554\" data-elementor-type=\"page\"\u003e\n\u003cdiv data-e-type=\"container\" data-element_type=\"container\" data-id=\"e081ffd\" class=\"wd-negative-gap elementor-element elementor-element-e081ffd e-flex e-con-boxed e-con e-parent e-lazyloaded\"\u003e\n\u003cdiv class=\"e-con-inner\"\u003e\n\u003cdiv data-e-type=\"container\" data-element_type=\"container\" data-id=\"a465110\" class=\"elementor-element elementor-element-a465110 e-con-full e-flex e-con e-child\"\u003e\n\u003cdiv data-widget_type=\"kbpb-product-tabs-advanced.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"68951fc\" class=\"elementor-element elementor-element-68951fc elementor-widget elementor-widget-kbpb-product-tabs-advanced\"\u003e\n\u003cdiv class=\"elementor-widget-container\"\u003e\n\u003cdiv class=\"kbpb-product-tabs-advanced\"\u003e\n\u003cdiv class=\"kbpb-tabs-content\"\u003e\n\u003cdiv id=\"tab-0\" class=\"kbpb-tab-pane active\"\u003e\n\u003cdiv class=\"kbpb-sections-content\"\u003e\n\u003cdiv id=\"section-what-is-semax\" class=\"kbpb-section\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eWhat is Semax?\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eSemax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide developed in Russia in the 1980s as an analog of the adrenocorticotropic hormone (ACTH) fragment 4-10. Unlike native ACTH, Semax exhibits profound neurological benefits without hormonal activity, making it uniquely suitable for cognitive enhancement and neuroprotection applications. The peptide's structure incorporates the ACTH(4-7) fragment at the N-terminus and a stabilizing Pro-Gly-Pro (PGP) tripeptide at the C-terminus, which significantly extends its metabolic half-life and therapeutic duration compared to unmodified ACTH fragments.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eSemax functions as a multifaceted neurotropic agent that crosses the blood-brain barrier, particularly when administered intranasally, allowing direct central nervous system access. The peptide has been approved for clinical use in Russia and is listed on the Russian List of Vital \u0026amp; Essential Drugs for treating ischemic stroke, transient ischemic attacks, memory and cognitive disorders, optic nerve diseases, and immune system support.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe peptide's mechanism of action involves multiple pathways that collectively contribute to its therapeutic effects. Semax rapidly elevates brain-derived neurotrophic factor (BDNF) expression in the hippocampus and frontal cortex within 20 minutes to 3 hours after administration, with BDNF protein levels increasing up to 1.4-fold. This upregulation of BDNF, a critical modulator of synaptic plasticity, supports neuronal survival, growth, and the formation of new synaptic connections essential for learning and memory processes.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eAdditionally, Semax activates dopaminergic and serotonergic neurotransmitter systems, influencing mood regulation, motivation, attention, and cognitive processing. The peptide demonstrates potent inhibition of enkephalin-degrading enzymes with an IC50 of 10 μM, more effective than traditional peptidase inhibitors. By preserving endogenous enkephalins, Semax may enhance natural pain modulation mechanisms and reduce inflammatory responses.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eGenome-wide transcriptional analyses reveal that Semax modulates the expression of hundreds of genes involved in immune response, vascular system function, inflammation control, and cellular stress responses. Three hours after cerebral ischemia, Semax influences genes affecting immune cell activity, mobility, and chemokine expression, while at 24 hours post-ischemia, its immunomodulatory effects intensify, suggesting a key role in neuroprotection through neuroimmune crosstalk.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe peptide exhibits excellent safety profiles across numerous clinical trials, with minimal reported adverse effects limited primarily to mild nasal irritation with intranasal administration and occasional glucose elevation in diabetic patients. Semax demonstrates no hormonal activity, no development of tolerance or dependence, and no significant drug interactions, making it suitable for both acute interventions and cognitive optimization protocols.\u003c\/p\u003e\n \n\u003ch4\u003eChemical Identity\u003c\/h4\u003e\nThe compound is characterized by its unique molecular structure and specific chemical properties that make it valuable for research applications.\n\u003cdiv class=\"pac-collapsible-section\"\u003e\n\u003cbutton type=\"button\" class=\"pac-toggle-btn\"\u003e\u003cspan class=\"toggle-text\"\u003eShow IUPAC Name\u003c\/span\u003e\u003cspan class=\"toggle-icon\"\u003e▼\u003c\/span\u003e\u003c\/button\u003e\n\u003cdiv class=\"pac-collapsible-content\"\u003e\n\u003cstrong\u003eSystematic IUPAC Name:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid\u003c\/div\u003e\n\u003c\/div\u003e\n \n\u003ch4\u003ePurity \u0026amp; Quality\u003c\/h4\u003e\nOur Semax is provided at research-grade purity, suitable for laboratory applications and experimental protocols. Each batch undergoes quality control testing to ensure consistency and reliability for your research needs.\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eImportant:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eThis product is intended for research purposes only and is not for human or veterinary use. It is sold for laboratory and scientific investigation only.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"section-semax-structure\" class=\"kbpb-section\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eSemax Structure\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e \n\u003cdiv class=\"peptide-structure-content\"\u003e\n\u003ch3\u003eChemical Structure\u003c\/h3\u003e\n\u003cdiv class=\"structure-images\"\u003e\n\u003cdiv class=\"structure-2d\"\u003e\n\u003ch4\u003e2D Structure\u003c\/h4\u003e\n\u003cimg height=\"60\" width=\"60\" alt=\"Semax 2D Structure\" src=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/image\/imgsrv.fcgi?cid=9811102\u0026amp;t=l\" class=\"peptide-structure-image\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"structure-3d\"\u003e\n\u003ch4\u003e3D Structure\u003c\/h4\u003e\n\u003cimg height=\"60\" width=\"60\" alt=\"Semax 3D Structure\" src=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/image\/imgsrv.fcgi?cid=9811102\u0026amp;t=l\u0026amp;3d=true\" class=\"peptide-structure-image\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"chemical-properties\"\u003e\n\u003ch3\u003eChemical Properties\u003c\/h3\u003e\n\u003ctable class=\"peptide-properties-table\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003eCAS Number\u003c\/th\u003e\n\u003ctd\u003e80714-61-0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular Formula\u003c\/th\u003e\n\u003ctd\u003eC37H51N9O10S\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular Weight\u003c\/th\u003e\n\u003ctd\u003e813.9 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr class=\"iupac-row\"\u003e\n\u003cth\u003eIUPAC Name\u003c\/th\u003e\n\u003ctd\u003e\n\u003cdiv class=\"iupac-collapsible\"\u003e\n\u003cbutton type=\"button\" class=\"iupac-toggle-btn\"\u003e\u003cspan class=\"toggle-text\"\u003eShow IUPAC Name\u003c\/span\u003e\u003cspan class=\"toggle-icon\"\u003e▼\u003c\/span\u003e\u003c\/button\u003e\n\u003cdiv class=\"iupac-content\"\u003e(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eInChIKey\u003c\/th\u003e\n\u003ctd\u003e\u003ccode\u003eAFEHBIGDWIGTEH-AQRCPPRCSA-N\u003c\/code\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp class=\"pubchem-link\"\u003e\u003ca rel=\"noopener noreferrer\" href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/9811102\" target=\"_blank\"\u003eView full compound data on PubChem →\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"section-semax-research\" class=\"kbpb-section\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eSemax Research\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e\n\u003cdiv class=\"peptide-research-content\"\u003e\n\u003cdiv class=\"research-articles\"\u003e\n\u003cdiv class=\"research-article\"\u003e\n\u003cdiv class=\"article-citation\"\u003e\n\u003ch4 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eCognitive Enhancement and Memory Function\u003c\/h4\u003e\n\u003cp\u003eSemax demonstrates significant cognitive-enhancing properties across multiple domains of brain function. Research published in Brain Research found that a single intranasal application of Semax (50 μg\/kg) resulted in a 1.4-fold increase in BDNF protein levels in the rat basal forebrain after 3 hours, accompanied by a 1.6-fold increase in trkB receptor phosphorylation and 2-3-fold increases in BDNF and trkB mRNA expression. This enhancement of the hippocampal BDNF\/trkB system correlates directly with improved learning and memory performance, as Semax-treated animals demonstrated distinct increases in conditioned avoidance reactions.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words\"\u003eHuman studies demonstrate practical cognitive benefits under demanding conditions. In a clinical evaluation of healthy but fatigued subjects following 8-hour work shifts, those receiving Semax achieved 71% accuracy on memory tests compared to 41% in control groups, with cognitive improvements persisting for up to 24 hours. The peptide's effects on learning were confirmed in animal models where Semax significantly decreased learning time and improved memory consolidation across multiple behavioral paradigms.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words\"\u003eStudies indicate that Semax improves attention span, focus, and sustained concentration by modulating dopaminergic activity in the prefrontal cortex, the brain region responsible for executive function and working memory. The peptide enhances both short-term and long-term memory retention, particularly under conditions of high cognitive demand, making it valuable for academic performance, professional productivity, and age-related cognitive preservation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words\"\u003eFunctional MRI studies in healthy humans show that intranasal Semax (total dose 1.2 mg) increases resting signal in the default mode network rostral subcomponent, a brain system critical for attention, awareness, and social cognition. This modulation suggests Semax enhances baseline cognitive processing efficiency even during rest states, potentially improving responsiveness and mental clarity throughout daily activities.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eDolotov OV, et al. \"Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.\" Journal of Neurochemistry. 2006;97(4):1005-1015.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16635254\/\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/16635254\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eDolotov OV, et al. \"Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.\" Brain Research. 2006;1117(1):54-60.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16996037\/\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/16996037\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eAgapova TY, et al. \"Time course of the expression of genes of brain-derived neurotrophic factor and nerve growth factor in the hippocampus and frontal cortex induced by semax in rats.\" Molecular Genetics, Microbiology and Virology. 2008;23(3):142-146.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/link.springer.com\/article\/10.3103\/S0891416808030063\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/link.springer.com\/article\/10.3103\/S0891416808030063\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eLebedeva IS, et al. \"Effects of Semax on the Default Mode Network of the Brain.\" Bulletin of Experimental Biology and Medicine. 2018;164(5):653-656.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/www.alzdiscovery.org\/uploads\/cognitive_vitality_media\/Semax-Cognitive-Vitality-For-Researchers.pdf\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/www.alzdiscovery.org\/uploads\/cognitive_vitality_media\/Semax-Cognitive-Vitality-For-Researchers.pdf\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eNeuroprotection and Stroke Recovery\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eSemax exhibits remarkable neuroprotective properties in cerebral ischemia and stroke recovery. Clinical trials demonstrate that Semax administration during the acute period of hemispheric ischemic stroke significantly enhances neurological recovery compared to conventional therapy alone. In a controlled study of 30 patients with acute ischemic stroke receiving Semax alongside standard treatment versus 80 control patients, researchers observed accelerated restoration of neurological functions, particularly motor disorders, with improvements documented through clinical rating scales, EEG mapping, and somatosensory evoked potential analysis.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eA genome-wide study investigating Semax's molecular mechanisms in permanent middle cerebral artery occlusion (pMCAO) revealed that the peptide altered expression of 96 genes 3 hours after ischemia and 68 genes at 24 hours post-occlusion. The most prominent effects involved immune system and vascular system genes, with Semax enhancing expression of genes that modulate immune cell amount and mobility while increasing chemokine and immunoglobulin gene expression. The peptide influenced processes accompanying blood vessel formation during early ischemia stages and vascular stabilization at later stages, suggesting that immunomodulation and vascular support are key mechanisms underlying neuroprotection.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIn a clinical study of 110 patients recovering from ischemic stroke, Semax treatment (6000 μg\/day for 10 days, two courses with 20-day interval) significantly increased plasma BDNF levels, which remained elevated throughout the study period. Patients with high BDNF levels following Semax administration demonstrated improved timing of rehabilitation, better motor performance on the British Medical Research Council scale, and enhanced Barthel index scores regardless of whether rehabilitation began early or late after stroke onset.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eProteomic analysis of rat brain tissue following transient middle cerebral artery occlusion (tMCAO) showed that Semax modulates key proteins involved in inflammation and cell death (MMP-9, c-Fos, JNK) while enhancing neuroprotective signaling through CREB activation. The peptide suppresses inflammatory gene expression (Il1b, Il6, Tnfa) while promoting neurotransmitter-related gene activation, creating a favorable environment for neural recovery and reducing secondary brain injury.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eMedvedeva EV, et al. \"The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.\" BMC Genomics. 2014;15:228.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3987924\/\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3987924\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eGusev EI, et al. \"Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study).\" Zhurnal Nevrologii i Psikhiatrii. 2001;101(6):26-34.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/11517472\/\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/11517472\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eGusev EI, et al. \"The efficacy of semax in the treatment of patients at different stages of ischemic stroke.\" Zhurnal Nevrologii i Psikhiatrii. 2017;117(3):38-45.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29798983\/\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/29798983\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eBobkova NV, et al. \"Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4–7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia–Reperfusion.\" Frontiers in Neuroscience. 2021;15:681950.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8226508\/\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8226508\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eMyasoedov NF, et al. \"Investigation of mechanisms of neuroprotective effect of Semax in acute period of ischemic stroke.\" Zhurnal Nevrologii i Psikhiatrii. 1999;99(5):15-19.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10358912\/\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/10358912\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eOxidative Stress Protection and Cellular Defense\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eSemax demonstrates potent antioxidant properties that protect neural tissue from various forms of oxidative damage. Animal studies show that Semax prevents oxidative damage caused by heavy metal poisoning, including lead exposure in the brain. The peptide protects against oxidative liver damage occurring with chronic stress and prevents oxidative damage to body tissues following stroke or heart attack, with researchers attributing improved recovery in part to these oxidative protection mechanisms.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eResearch published in Doklady Biological Sciences examined Semax effects on heavy metal poisoning in rats compared with ascorbic acid, a known antioxidant. Heavy metal salts inhibited avoidance responses in rat subjects, and Semax counteracted these effects as effectively as ascorbic acid, confirming the peptide's antioxidant properties. Additional studies demonstrate that Semax moderates copper-induced cytotoxicity in cell lines, forming stable complexes with copper(II) ions and preventing copper-induced cell death in neuroblastoma and endothelial cells.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThe peptide's antioxidant activity extends to preventing amyloid-beta aggregation, particularly in the presence of copper ions. Research shows Semax inhibits fiber formation by interfering with the fibrillogenesis of Aβ:Cu2+ complexes in a concentration-dependent manner, both in buffer solutions and in the presence of model cell membranes. This anti-aggregating property, combined with its ability to prevent membrane disruption, suggests potential applications in preventing protein misfolding diseases associated with oxidative stress and metal ion dysregulation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eMechanistically, Semax enhances antioxidant enzyme activity and cellular protection systems while improving mitochondrial protection and cellular energy metabolism. The peptide reduces oxidative stress markers and prevents cellular damage through activation of stress response pathways and regulation of genes containing antioxidant response elements (ARE). These protective mechanisms make Semax particularly valuable during periods of metabolic stress, ischemia, or exposure to environmental toxins.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eMedvedeva EV, et al. \"Heavy Metal Salt-Induced Oxidative Stress in Rats Can Be Alleviated by the Peptide Semax.\" Doklady Biological Sciences. 2016;470(1):205-208.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/particlepeptides.com\/en\/content\/37-semax\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/particlepeptides.com\/en\/content\/37-semax\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eTabbì G, et al. \"Semax, an ACTH4-10 peptide analog with high affinity for copper(II) ion and protective ability against metal induced cell toxicity.\" Journal of Inorganic Biochemistry. 2015;142:8-16.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0162013414002505\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0162013414002505\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eZimbone S, et al. \"Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models.\" ACS Chemical Neuroscience. 2022;13(3):345-360.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8855339\/\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8855339\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eOptic Nerve Protection and Visual Function Recovery\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eClinical studies demonstrate Semax's efficacy in treating various optic nerve pathologies. A comprehensive clinical trial evaluated Semax in patients with vascular, toxic-allergic, and inflammatory diseases of the optic nerve, as well as partial optic nerve atrophy. Patients were divided into groups receiving intranasal Semax drops, endonasal electrophoresis of Semax, or standard treatment alone. Addition of Semax to the therapeutic regimen significantly improved the intensity and rate of recovery across multiple visual function parameters.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eSemax treatment effectively protected nervous tissue from injury consequences, particularly during acute stages of optic nerve disease. Clinical improvements included enhanced visual acuity, extension of total visual field, increased electrical sensitivity and conductivity of the optic nerve, and improved visual evoked potential parameters. These objective measurements confirmed that Semax provided genuine neuroprotective effects beyond subjective symptom relief.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIn glaucomatous optic neuropathy studies where intraocular pressure was normalized, Semax demonstrated advantages over traditional neuroprotective treatments. Electrophysiological and computer examination methods revealed superior outcomes in patients receiving Semax as part of a neuroprotective therapy complex. The efficiency is attributed to Semax's dual pathogenetic activity possessing both neuroprotective and neurotrophic effects, supporting optic nerve survival and function even when mechanical pressure factors are controlled.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eResearch in diabetic retinopathy patients showed that endonasal electrophoresis of 0.1% Semax produced the most pronounced and long-lasting positive effects on visual, perimetric, and electrophysiological function, with benefits persisting up to 12 months. This sustained improvement suggests Semax promotes genuine structural and functional recovery rather than temporary symptomatic relief, making it valuable for progressive neurological conditions affecting vision.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003ePolunin GS, et al. \"Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease.\" Vestnik Oftalmologii. 2000;116(1):15-18.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10741256\/\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/10741256\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eKurysheva NI, et al. \"Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone.\" Vestnik Oftalmologii. 2001;117(4):5-8.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/11569188\/\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/11569188\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eSheremet NL, et al. \"An experimental substantiation for using the 'Semax' neuroprotector in the treatment of optic-nerve diseases.\" Vestnik Oftalmologii. 2004;120(6):25-27.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15678666\/\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/15678666\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003ePain Modulation and Enkephalin Preservation\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eSemax exhibits dose-dependent inhibition of enkephalin-degrading enzymes in human serum with an IC50 of 10 μM, demonstrating more pronounced effects than traditional peptidase inhibitors including puromycin (IC50 10 mM) and bacitracin. This inhibitory activity extends to both the heptapeptide Semax and its pentapeptide fragments, while shorter tri-, tetra-, and hexapeptide fragments showed no such effect. Since these enzymes degrade not only enkephalins but also other regulatory peptides, this inhibitory activity represents a key mechanism of Semax's biological effects.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEnkephalins are endogenous opioid peptides that play crucial roles in pain modulation, stress response regulation, immune function, and emotional behavior. By inhibiting their degradation, Semax effectively prolongs the half-life and enhances the activity of these natural analgesic compounds. Research demonstrates that preservation of enkephalins contributes to pain relief and reduction of inflammatory responses, as these peptides decrease pain perception, reduce inflammation, and increase immune cell activity.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAnimal studies investigating pain sensitivity using the paw-withdrawal test showed that the amino acid at position 1 of Semax analogs plays a key role in mediating analgesic effects. While truncations of N-terminal residues eliminated analgesic activity, strategic modifications preserved pain-modulating properties. The peptide's effects on pain pathways appear to involve both direct enkephalin preservation and modulation of opioid receptor systems, though the analgesic effect was absent with intranasal administration in some studies, suggesting route-dependent efficacy.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAdditionally, Semax's anti-inflammatory properties complement its pain-modulating effects. The peptide reduces production of pro-inflammatory cytokines and modulates inflammatory signaling pathways, providing a multi-faceted approach to pain management that addresses both sensory and inflammatory components without the tolerance, dependence, or severe side effects associated with conventional opioid medications.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eKost NV, et al. \"Semax and Selank Inhibit the Enkephalin-Degrading Enzymes of Human Serum.\" Russian Journal of Bioorganic Chemistry. 2001;27(3):180-183.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/link.springer.com\/article\/10.1023\/A:1011373002885\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/link.springer.com\/article\/10.1023\/A:1011373002885\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eKost NV, et al. \"Semax and selank inhibit the enkephalin-degrading enzymes from human serum.\" Bioorganicheskaia Khimiia. 2001;27(3):180-183.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/11443939\/\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/11443939\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eMood Regulation and Stress Resilience\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eSemax demonstrates significant anxiolytic and antidepressant properties mediated through activation of serotonergic and dopaminergic brain systems. A 2007 study analyzed effects of chronic Semax administration on exploratory activity, anxiety level, and depression-like behavior in rats. While Semax did not significantly influence exploratory activity in non-stressogenic environments, it produced pronounced anxiolytic and antidepressant effects. Researchers concluded these benefits derive from activation of the brain serotonergic system and increased BDNF expression in the hippocampus, both critical for mood regulation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThe peptide rapidly elevates levels and expression of BDNF and its signaling receptor tropomyosin receptor kinase B (TrkB) in the hippocampus, structures centrally involved in stress response and emotional processing. This upregulation of the BDNF system supports neuroplasticity and stress resilience, allowing the brain to adapt more effectively to challenging circumstances. Studies show Semax attenuates behavioral effects of chronic stress exposure and normalizes stress-associated behavioral abnormalities.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAnimal models demonstrate that Semax potentiates dopaminergic transmission in the striatum, enhancing motivation, reward processing, and goal-directed behavior. This dopaminergic modulation contributes to improved mood stability and reduced symptoms of depression, as dopamine plays essential roles in pleasure, motivation, and emotional regulation. The peptide's ability to balance both serotonergic and dopaminergic systems provides comprehensive mood support without the emotional blunting or discontinuation syndromes associated with conventional antidepressants.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eClinical observations suggest Semax may be particularly effective for individuals experiencing cognitive fatigue, burnout, or stress-related mood disturbances. The peptide's dual action of enhancing cognitive performance while supporting emotional resilience makes it uniquely suited for high-stress professional environments or recovery from trauma where both mental clarity and emotional stability are essential.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eEremin KO, et al. \"Effects of Semax on exploratory activity and anxiety in white rats.\" Ross Fiziol Zh Im I M Sechenova. 2007;93(9):991-997.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/particlepeptides.com\/en\/content\/37-semax\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/particlepeptides.com\/en\/content\/37-semax\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eShadrina MI, et al. \"Effects of Semax on dopaminergic and serotonergic brain systems.\" Bulletin of Experimental Biology and Medicine. 2010;150(1):77-80.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/en.wikipedia.org\/wiki\/Semax\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/en.wikipedia.org\/wiki\/Semax\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eImmunomodulation and Anti-Inflammatory Effects\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eGenome-wide transcriptional analysis reveals that Semax profoundly affects immune system gene expression in conditions of cerebral ischemia. Three hours after permanent middle cerebral artery occlusion, Semax influenced expression of genes affecting immune cell activity and mobility. Twenty-four hours post-ischemia, the peptide's immunomodulatory effects intensified considerably, with Semax predominantly enhancing expression of genes related to immune response, increasing chemokine and immunoglobulin gene expression, and modulating the amount and mobility of immune cells.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThe peptide markedly affects immune response by altering expression of genes that encode chemokines and immunoglobulins, substances critical for coordinating immune cell trafficking and antibody production. Research demonstrates that Semax's neuroprotective effects in stroke likely derive from these immunomodulating properties combined with its impact on the vascular system during ischemia. This neuroimmune crosstalk represents a key mechanism through which Semax protects brain tissue from ischemic damage.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eStudies show that Semax reduces production of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α, which contribute to secondary brain injury following ischemia or trauma. By suppressing these inflammatory mediators at the gene expression level, Semax creates an environment more conducive to neural repair and recovery. The peptide's ability to modulate inflammation without broadly suppressing immune function distinguishes it from traditional anti-inflammatory medications.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAdditionally, Semax enhances antigen presentation signaling pathways and intensifies interferon signaling, suggesting it can support appropriate immune responses while reducing harmful neuroinflammation. This balanced immunomodulation makes Semax potentially valuable not only for acute neurological injuries but also for chronic neurodegenerative conditions where controlled inflammation plays a role in disease progression.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eMedvedeva EV, et al. \"The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.\" BMC Genomics. 2014;15:228.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/link.springer.com\/article\/10.1186\/1471-2164-15-228\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/link.springer.com\/article\/10.1186\/1471-2164-15-228\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words pl-2\"\u003eDmitrieva VG, et al. \"Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia.\" Cellular and Molecular Neurobiology. 2010;30(1):71-79.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/www.researchgate.net\/publication\/325375504_The_efficacy_of_semax_in_the_tretament_of_patients_at_different_stages_of_ischemic_stroke\" class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\"\u003ehttps:\/\/www.researchgate.net\/publication\/325375504_The_efficacy_of_semax_in_the_tretament_of_patients_at_different_stages_of_ischemic_stroke\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"research-disclaimer\"\u003e\u003cem\u003e\u003cstrong\u003eDisclaimer:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eThe research articles listed above are for informational purposes only. This product is intended for research use only and not for human or veterinary use.\u003c\/em\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv data-e-type=\"container\" data-element_type=\"container\" data-id=\"c8b3f0a\" class=\"wd-negative-gap elementor-element elementor-element-c8b3f0a e-flex e-con-boxed e-con e-parent e-lazyloaded\"\u003e\n\u003cdiv class=\"e-con-inner\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/main\u003e\u003c\/div\u003e\n\u003cdiv class=\"wd-prefooter\"\u003e\n\u003cdiv class=\"container wd-entry-content\"\u003e⊗PRODUCTS ARE INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly prohibited by law. Products should only be handled by licensed, qualified professionals. Products sold are not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food, or cosmetic.\u003c\/div\u003e\n\u003c\/div\u003e","brand":"CHEATCODES","offers":[{"title":"5mg","offer_id":44420748476531,"sku":null,"price":29.99,"currency_code":"USD","in_stock":true},{"title":"10mg","offer_id":44420748509299,"sku":null,"price":59.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0681\/2316\/4787\/files\/semax_10mg_92ad720e-9e57-4297-88b6-f754d29e01d0.jpg?v=1775962589"},{"product_id":"selank","title":"Selank","description":"\u003cdiv class=\"wd-page-content main-page-wrapper\"\u003e\u003cmain role=\"main\" class=\"wd-content-layout content-layout-wrapper wd-builder-off\" id=\"main-content\"\u003e\n\u003cdiv role=\"main\" id=\"content\" class=\"site-content col-lg-12\"\u003e\n\u003cdiv class=\"container\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"content-area col-sm-12\"\u003e\n\u003cdiv class=\"elementor elementor-6554\" data-elementor-id=\"6554\" data-elementor-type=\"page\"\u003e\n\u003cdiv data-e-type=\"container\" data-element_type=\"container\" data-id=\"e081ffd\" class=\"wd-negative-gap elementor-element elementor-element-e081ffd e-flex e-con-boxed e-con e-parent e-lazyloaded\"\u003e\n\u003cdiv class=\"e-con-inner\"\u003e\n\u003cdiv data-e-type=\"container\" data-element_type=\"container\" data-id=\"a465110\" class=\"elementor-element elementor-element-a465110 e-con-full e-flex e-con e-child\"\u003e\n\u003cdiv data-widget_type=\"kbpb-product-tabs-advanced.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"68951fc\" class=\"elementor-element elementor-element-68951fc elementor-widget elementor-widget-kbpb-product-tabs-advanced\"\u003e\n\u003cdiv class=\"elementor-widget-container\"\u003e\n\u003cdiv class=\"kbpb-product-tabs-advanced\"\u003e\n\u003cdiv class=\"kbpb-tabs-content\"\u003e\n\u003cdiv id=\"tab-0\" class=\"kbpb-tab-pane active\"\u003e\n\u003cdiv class=\"kbpb-sections-content\"\u003e\n\u003cdiv id=\"section-what-is-selank\" class=\"kbpb-section\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eWhat is Selank?\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eSelank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences as a stable analog of tuftsin, an endogenous tetrapeptide fragment of immunoglobulin G. The peptide was specifically engineered by elongating the tuftsin sequence with three additional amino acids (Pro-Gly-Pro) at the C-terminus to enhance metabolic stability and extend duration of action, creating a compound with pronounced anxiolytic and nootropic properties.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eSelank functions as a multi-target regulatory peptide that modulates neurotransmitter systems in the central nervous system while simultaneously influencing immune function. The peptide crosses the blood-brain barrier and primarily acts through allosteric modulation of GABA-A receptors, producing anxiolytic effects similar to classical benzodiazepine drugs but without their associated side effects including sedation, muscle relaxation, dependence, or withdrawal syndrome. Unlike benzodiazepines, Selank demonstrates additional cognitive-enhancing and psychostimulant properties that improve mental clarity and learning capacity.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe peptide's mechanism of action involves complex interactions with multiple neurotransmitter systems. Selank influences the expression and activity of genes encoding GABA receptors, dopamine receptors (particularly D1, D2, and D5 subtypes), and serotonin receptors in the frontal cortex and hippocampus. Research demonstrates that Selank administration causes significant changes in the expression of 45 genes involved in neurotransmission within one hour, affecting major receptor subunits, transporters, and ion channels critical for neuronal signaling.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eA unique aspect of Selank's action is its potent inhibition of enkephalin-degrading enzymes in human serum. Enkephalins are endogenous opioid peptides that regulate pain perception, emotional responses, and stress adaptation. By preventing their rapid degradation, Selank maintains higher enkephalin levels, contributing to its anxiolytic and stress-protective effects. This inhibitory activity is more pronounced than that of conventional peptidase inhibitors such as bacitracin and puromycin.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eSelank also demonstrates significant immunomodulatory properties through regulation of cytokine gene expression. Studies show the peptide causes alterations in the expression of 34 genes involved in inflammatory processes, including chemokines, cytokines, and their receptors. The peptide influences key immune regulatory genes such as Bcl6, which plays a central role in immune system development, along with genes encoding complement component C3, caspase-1, and various interleukin receptors.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eResearch indicates that Selank levels in the body are influenced by stress conditions, with the peptide demonstrating adaptogenic properties by normalizing physiological responses to chronic stress. Clinical studies have established Selank's efficacy in treating generalized anxiety disorder and neurasthenia, with therapeutic effects comparable to established anxiolytic medications but with a superior safety profile and absence of cognitive side effects.\u003c\/p\u003e\n \n\u003ch4\u003eChemical Identity\u003c\/h4\u003e\nThe compound is characterized by its unique molecular structure and specific chemical properties that make it valuable for research applications.\n\u003cdiv class=\"pac-collapsible-section\"\u003e\n\u003cbutton type=\"button\" class=\"pac-toggle-btn\"\u003e\u003cspan class=\"toggle-text\"\u003eShow IUPAC Name\u003c\/span\u003e\u003cspan class=\"toggle-icon\"\u003e▼\u003c\/span\u003e\u003c\/button\u003e\n\u003cdiv class=\"pac-collapsible-content\"\u003e\n\u003cstrong\u003eSystematic IUPAC Name:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch4\u003ePurity \u0026amp; Quality\u003c\/h4\u003e\nOur Selank is provided at research-grade purity, suitable for laboratory applications and experimental protocols. Each batch undergoes quality control testing to ensure consistency and reliability for your research needs.\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eImportant:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eThis product is intended for research purposes only and is not for human or veterinary use. It is sold for laboratory and scientific investigation only.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"section-selank-structure\" class=\"kbpb-section\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eSelank Structure\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e \n\u003cdiv class=\"peptide-structure-content\"\u003e\n\u003ch3\u003eChemical Structure\u003c\/h3\u003e\n\u003cdiv class=\"structure-images\"\u003e\n\u003cdiv class=\"structure-2d\"\u003e\n\u003ch4\u003e2D Structure\u003c\/h4\u003e\n\u003cimg alt=\"Selank 2D Structure\" src=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/image\/imgsrv.fcgi?cid=11765600\u0026amp;t=l\" class=\"peptide-structure-image\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"structure-3d\"\u003e\n\u003ch4\u003e3D Structure\u003c\/h4\u003e\n\u003cimg alt=\"Selank 3D Structure\" src=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/image\/imgsrv.fcgi?cid=11765600\u0026amp;t=l\u0026amp;3d=true\" class=\"peptide-structure-image\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"chemical-properties\"\u003e\n\u003ch3\u003eChemical Properties\u003c\/h3\u003e\n\u003ctable class=\"peptide-properties-table\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003eCAS Number\u003c\/th\u003e\n\u003ctd\u003e129954-34-3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular Formula\u003c\/th\u003e\n\u003ctd\u003eC33H57N11O9\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular Weight\u003c\/th\u003e\n\u003ctd\u003e751.9 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr class=\"iupac-row\"\u003e\n\u003cth\u003eIUPAC Name\u003c\/th\u003e\n\u003ctd\u003e\n\u003cdiv class=\"iupac-collapsible\"\u003e\n\u003cbutton type=\"button\" class=\"iupac-toggle-btn\"\u003e\u003cspan class=\"toggle-text\"\u003eShow IUPAC Name\u003c\/span\u003e\u003cspan class=\"toggle-icon\"\u003e▼\u003c\/span\u003e\u003c\/button\u003e\n\u003cdiv class=\"iupac-content\"\u003e(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eInChIKey\u003c\/th\u003e\n\u003ctd\u003e\u003ccode\u003eJTDTXGMXNXBGBZ-YVHUGQOKSA-N\u003c\/code\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp class=\"pubchem-link\"\u003e\u003ca rel=\"noopener noreferrer\" href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/11765600\" target=\"_blank\"\u003eView full compound data on PubChem →\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"section-selank-research\" class=\"kbpb-section\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eSelank Research\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e\n\u003cdiv class=\"peptide-research-content\"\u003e\n\u003cdiv class=\"research-articles\"\u003e\n\u003cdiv class=\"research-article\"\u003e\n\u003cdiv class=\"article-citation\"\u003e\n\u003ch3 class=\"font-claude-response-subheading text-text-100 mt-1 -mb-1.5\"\u003eResearch Applications\u003c\/h3\u003e\n\u003ch4 class=\"font-claude-response-body-bold text-text-100 mt-1\"\u003eAnxiety and Stress Management\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eSelank has been extensively studied for its anxiolytic properties in both preclinical and clinical settings, demonstrating efficacy comparable to benzodiazepine medications without their characteristic drawbacks. In a controlled clinical trial of 62 patients with generalized anxiety disorder (GAD) and neurasthenia, Selank (administered to 30 patients) was compared directly to medazepam, a conventional benzodiazepine tranquilizer. Patient assessments using validated psychometric scales (Hamilton Anxiety Rating Scale, Zung Self-Rating Anxiety Scale, and Clinical Global Impression) revealed that both drugs produced similar anxiolytic effects, but Selank additionally demonstrated antiasthenic and psychostimulant properties absent with medazepam treatment.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eClinical research reveals that Selank exhibits remarkable individual response variability, with approximately 40% of patients classified as \"rapid responders\" experiencing abrupt reduction in anxiety symptoms within 1-3 days of treatment initiation. In this subset, Hamilton Anxiety Rating Scale scores decreased from a mean of 20.3 to 7.0 by day three, representing a highly significant clinical improvement. The remaining 60% of patients demonstrated gradual but consistent symptom reduction over 14 days, with final anxiety scores comparable to the rapid responder group.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eComparative studies examining Selank in combination with phenazepam versus phenazepam monotherapy in patients with anxiety-phobic and somatoform disorders (70 total patients) demonstrated that combination treatment significantly reduced the adverse side effects typically associated with benzodiazepines. The combined approach decreased attention and memory impairment, asthenia, excessive sedation, prolonged sleep duration, sexual disturbances, emotional indifference, and orthostatic hypotension—both during active treatment and following tranquilizer withdrawal. These findings suggest Selank may enable lower benzodiazepine dosages while maintaining therapeutic efficacy.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe molecular mechanisms underlying Selank's anxiolytic effects involve modulation of the GABAergic system through gene expression changes. Research analyzing 84 genes related to neurotransmission in rat frontal cortex tissue revealed that Selank administration (300 μg\/kg) caused significant alterations in expression of 45 genes at one hour and 22 genes at three hours post-administration. These changes showed positive correlation with those induced by direct GABA administration, supporting the hypothesis that Selank acts through allosteric modulation of GABA-A receptor function rather than direct receptor binding.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eStudies examining enkephalin metabolism provide additional insight into Selank's anxiolytic mechanism. Patients with generalized anxiety disorder exhibit considerably shortened enkephalin half-life and reduced total enkephalinase activity in blood, likely due to low concentrations of endogenous enzyme inhibitors. Selank dose-dependently inhibits enzymatic hydrolysis of plasma enkephalin with an IC50 of approximately 15 μM, demonstrating greater potency than conventional peptidase inhibitors. This preservation of enkephalin activity contributes significantly to anxiety reduction and stress resilience.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eAnimal studies demonstrate that Selank effectively attenuates behavioral manifestations of anxiety and chronic stress across different phenotypes of emotional stress reactions. In mouse models subjected to unpredictable chronic mild stress, Selank administration prevented the deterioration of anxiety indicators and enhanced the anxiolytic effects of diazepam when used in combination. The peptide's stress-protective activity extends to modulation of pro-inflammatory cytokines, with studies showing Selank effectively reduces concentrations of IL-1β, IL-6, and TGF-β1 while restoring levels of anti-inflammatory cytokine IL-4 in stressed animals.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc space-y-2.5 pl-7\"\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eZozulya AA, et al. \"Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia.\" Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/18454096\/\" class=\"underline\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/18454096\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eEuropean Psychiatry. \"Rapid and slow response during treatment of generalized anxiety disorder with peptide anxiolytic Selank.\" 2012;27(Suppl 1):1.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/www.cambridge.org\/core\/journals\/european-psychiatry\/article\/p1114-rapid-and-slow-response-during-treatment-of-generalized-anxiety-disorder-with-peptide-anxiolytic-selank\/7A497218D37084BD079EFE143126F56E\" class=\"underline\"\u003ehttps:\/\/www.cambridge.org\/core\/journals\/european-psychiatry\/article\/p1114-rapid-and-slow-response-during-treatment-of-generalized-anxiety-disorder-with-peptide-anxiolytic-selank\/7A497218D37084BD079EFE143126F56E\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eDorofeeva OA, et al. \"Optimization of the treatment of anxiety disorders with selank.\" Eksp Klin Farmakol. 2009;72(2):6-10.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26356395\/\" class=\"underline\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/26356395\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eVolkova A, et al. \"Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.\" Front Pharmacol. 2016;7:31.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4757669\/\" class=\"underline\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4757669\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eKasian A, et al. \"Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.\" Behav Neurol. 2017;2017:5091027.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5322660\/\" class=\"underline\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5322660\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eKost NV, et al. \"The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.\" Zh Vyssh Nerv Deiat Im I P Pavlova. 2001;51(5):605-613.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/11550013\/\" class=\"underline\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/11550013\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"font-claude-response-body-bold text-text-100 mt-1\"\u003eCognitive Enhancement and Memory\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eSelank demonstrates significant nootropic properties through enhancement of learning, memory consolidation, and cognitive performance. Preclinical studies in Wistar rats using food-reward conditioned reflex paradigms revealed that a single injection of Selank (300 μg\/kg) administered during the consolidation phase significantly enhanced memory trace stability for up to 30 days post-training. This memory-enhancing effect was accompanied by activation of serotonin metabolism in the hypothalamus and caudal brainstem, with increased 5-HT turnover observed from 30 minutes to 2 hours following peptide administration.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eResearch examining Selank's effects on learning processes in rats with varying phenotypes of emotional and stress reactions demonstrated that the peptide significantly activated learning in animals with initially poor learning ability. In conditioned active avoidance reflex tests, Selank (300 μg\/kg) significantly enhanced the learning process in rats exhibiting passive stress response phenotypes. The nootropic effects manifested after a single dose on the first day of experimentation, indicating rapid onset of cognitive enhancement.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eStudies investigating Selank's protective effects against alcohol-induced cognitive impairment provide compelling evidence of its memory-preserving properties. In rats receiving 10% ethanol as their sole fluid source for 30 weeks, Selank treatment (0.3 mg\/kg daily for 7 days, administered intraperitoneally) produced cognitive-stimulating effects in 9-month-old rats not exposed to ethanol and prevented the formation of ethanol-induced memory and attention disturbances that typically develop during alcohol withdrawal. The object recognition test demonstrated that Selank effectively maintained cognitive function despite chronic alcohol exposure.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe molecular basis of Selank's cognitive enhancement involves modulation of brain-derived neurotrophic factor (BDNF) expression. Research examining BDNF levels in rat brain structures revealed that intranasal Selank administration rapidly regulates BDNF expression in the hippocampus—a critical region for memory formation and consolidation. Time-dependent studies showed that Selank increased BDNF mRNA expression several hours after administration, with protein levels initially dropping briefly before rising above baseline. This biphasic pattern suggests Selank engages both rapid signaling cascades and slower genomic mechanisms to ultimately increase BDNF protein production.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eAnalysis of gene expression changes in rat hippocampus following Selank administration identified alterations in dopamine receptor gene expression, particularly Drd5, which plays a key role in memory formation and learning processes by ensuring long-term potentiation. The peptide's influence on dopaminergic signaling contributes to enhanced cognitive processing, improved focus, and better retention of learned information.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eSelank's nootropic effects extend to protection against age-related cognitive decline. Studies demonstrate that the peptide positively influences memory disturbances associated with aging, particularly those complicated by chronic conditions such as alcohol use. The peptide's ability to regulate BDNF content in both the hippocampus and prefrontal cortex—two brain regions critical for executive function and memory—underlies its protective effects against cognitive deterioration.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eClinical observations indicate that Selank produces mild nootropic effects in patients with anxiety disorders, improving concentration, mental clarity, and information processing without the cognitive impairment or memory problems associated with benzodiazepine anxiolytics. This dual action—reducing anxiety while enhancing cognition—distinguishes Selank from conventional anxiolytic medications that typically impair cognitive function.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc space-y-2.5 pl-7\"\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eSokolov OY, et al. \"Experimental optimization of learning and memory processes by selank.\" Zh Vyssh Nerv Deiat Im I P Pavlova. 2010;60(5):505-512.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20919548\/\" class=\"underline\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/20919548\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eNadorova AV, et al. \"Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.\" Bull Exp Biol Med. 2019;167(6):843-846.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31625062\/\" class=\"underline\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/31625062\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eInozemtseva LS, et al. \"Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo.\" Dokl Biol Sci. 2008;421:241-243.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/link.springer.com\/article\/10.1134\/S0012496608040066\" class=\"underline\"\u003ehttps:\/\/link.springer.com\/article\/10.1134\/S0012496608040066\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eSokolov OY, et al. \"Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions.\" Bull Exp Biol Med. 2002;133(2):133-135.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12432865\/\" class=\"underline\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/12432865\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"font-claude-response-body-bold text-text-100 mt-1\"\u003eNeuroprotection and Brain Health\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eSelank demonstrates multiple neuroprotective mechanisms that support brain health through modulation of neurotrophic factors, reduction of oxidative stress, and protection against neuroinflammation. The peptide's influence on brain-derived neurotrophic factor (BDNF) expression represents a primary neuroprotective pathway. BDNF is a critical neurotrophin that supports neuronal survival, promotes synaptic plasticity, and facilitates neurogenesis—all essential processes for maintaining cognitive function and protecting against neurodegenerative conditions.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eResearch examining Selank's interaction with GABAergic neurotransmission and neurotrophic factor signaling revealed that BDNF plays a central role in the peptide's neuroprotective effects. Gene set enrichment analysis of neuroblastoma cells (IMR-32) incubated with Selank showed that the peptide influences biological processes involved in neurotransmission, with the \"gamma-aminobutyric acid signaling pathway\" identified as highly significant and BDNF positioned as a central regulatory factor in this network.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe peptide exhibits potent antioxidant properties that protect neural tissue from oxidative damage. Animal studies demonstrate that Selank administration in doses of 100 and 300 μg\/kg significantly decreased free radical levels in liver tissue, indicating systemic antioxidant activity that extends to protection of neuronal cells. Oxidative stress occurs when reactive oxygen species (ROS) production exceeds the body's neutralization capacity, leading to cellular damage particularly detrimental to neurons. Selank's antioxidant action helps maintain redox balance and protects neurons from oxidative injury.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eSelank's anti-inflammatory properties contribute significantly to its neuroprotective profile. Studies examining inflammation-related gene expression in mouse spleen following Selank administration (100 μg\/kg, single intraperitoneal injection) demonstrated significant alterations in 34 genes involved in inflammatory processes. Real-time PCR analysis revealed dynamic changes in expression of key inflammatory mediators including complement component C3 (showing a 3-fold decrease at 30 minutes), caspase-1, interleukin-2 receptor gamma chain (Il2rg), and chemokine receptor Xcr1. These changes indicate that Selank modulates inflammatory pathways at the molecular level, potentially reducing neuroinflammation that contributes to cognitive decline and neurodegeneration.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe peptide's inhibition of enkephalin-degrading enzymes provides an additional neuroprotective mechanism. Enkephalins are endogenous opioid peptides that not only regulate emotional responses but also exert neuroprotective effects through opioid receptor activation. Studies demonstrate that Selank inhibits these degrading enzymes with an IC50 of approximately 15-20 μM, showing greater potency than conventional peptidase inhibitors such as puromycin (IC50 10 mM) and bacitracin. This preservation of enkephalin activity supports neuronal resilience during metabolic stress and inflammatory challenges.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eResearch indicates that Selank's neuroprotective effects extend to protection against stress-induced neuronal damage. Chronic stress typically reduces BDNF expression in the hippocampus, particularly in the dentate gyrus, leading to impaired neuroplasticity and cognitive dysfunction. Selank administration helps maintain or restore BDNF levels under stress conditions, counteracting the negative effects of chronic stress on brain structure and function.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe peptide demonstrates hepatoprotective effects that indirectly support brain health through systemic metabolic regulation. Studies in rats show that Selank administration (300 and 1000 μg\/kg) restored hepatocyte structure and reduced markers of liver damage. Since the liver plays a crucial role in detoxification and metabolic homeostasis, Selank's protective effects on hepatic function contribute to overall neuroprotection by maintaining optimal systemic metabolism and reducing circulating toxins that could affect brain function.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc space-y-2.5 pl-7\"\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eFilatova E, et al. \"GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells.\" Front Pharmacol. 2017;8:89.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5328971\/\" class=\"underline\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5328971\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eKolomin TA, et al. \"The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action.\" Immunobiology. 2013;218(11):1407-1413.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0161589013005440\" class=\"underline\"\u003ehttps:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0161589013005440\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eKolomin TA, et al. \"Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank.\" Immunobiology. 2011;216(9):998-1003.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0167011511000863\" class=\"underline\"\u003ehttps:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0167011511000863\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eKost NV, et al. \"Semax and Selank Inhibit the Enkephalin-Degrading Enzymes of Human Serum.\" Russian Journal of Bioorganic Chemistry. 2001;27(2):156-159.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/link.springer.com\/article\/10.1023\/A:1011373002885\" class=\"underline\"\u003ehttps:\/\/link.springer.com\/article\/10.1023\/A:1011373002885\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"font-claude-response-body-bold text-text-100 mt-1\"\u003eImmune Function and Antiviral Activity\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eSelank exhibits significant immunomodulatory properties through regulation of cytokine expression and modulation of immune cell activity, demonstrating effects that extend beyond its central nervous system actions. As a synthetic analog of tuftsin—an endogenous immunomodulatory tetrapeptide—Selank retains and enhances the immune-regulating functions of its parent molecule while exhibiting improved stability and bioavailability.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eResearch examining Selank's antiviral properties against influenza A\/Aichi 2\/68 virus (H3N2) in both in vitro and in vivo systems revealed pronounced antiviral effects. The peptide demonstrated highest efficacy when administered 24 hours before viral inoculation in cell culture (preventive use scheme), completely suppressing viral reproduction under these conditions. In vivo studies in laboratory animals showed that preventive administration of Selank resulted in the highest survival rates among infected subjects.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe molecular mechanisms underlying Selank's antiviral activity involve modulation of interferon and cytokine gene expression. In vivo studies demonstrated that Selank administration induced gene expression of interferon-alpha (IFN-α) without affecting interleukin-4 (IL-4), interleukin-10 (IL-10), or tumor necrosis factor-alpha (TNF-α) under baseline conditions. This selective induction of IFN-α—a key antiviral cytokine—suggests Selank's mechanism involves modulation of the Th1\/Th2\/Treg cytokine equilibrium both directly and indirectly through central nervous system pathways.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eStudies examining the breadth of Selank's antiviral activity reveal efficacy against multiple viral pathogens including human influenza B\/Ohio 01\/05 virus, avian influenza virus (H5N1), herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), cytomegalovirus (CMV), and murine encephalomyocarditis virus (EMCV). This broad-spectrum antiviral activity, combined with the peptide's favorable safety profile, positions Selank as a promising immunomodulatory agent for viral infection prevention and management.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eAnalysis of Selank's effects on inflammatory gene expression in immune tissue provides insight into its immunomodulatory mechanisms. Studies using real-time PCR to examine 84 inflammation-related genes in mouse spleen tissue following Selank administration (100 μg\/kg) revealed significant changes in 34 genes at 6 and 24 hours post-injection. The Bcl6 gene, which plays a central role in immune system formation and development, exhibited particularly significant expression changes. Additional genes showing altered expression included those encoding chemokines, cytokines, and their receptors—key mediators of immune responses.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eTemporal dynamics studies revealed that Selank's active dipeptide fragment Gly-Pro contributes substantially to the peptide's immunomodulatory effects. Analysis of specific inflammatory genes including complement component C3, caspase-1 (Casp1), interleukin-2 receptor gamma chain (Il2rg), and chemokine receptor Xcr1 demonstrated that both full-length Selank and its Gly-Pro fragment induced similar expression changes, with a 3-fold decrease in C3 mRNA levels observed just 30 minutes after administration.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eClinical studies examining Selank's immunomodulatory effects in patients with anxiety-asthenic disorders and depression revealed that 14 days of Selank administration completely suppressed interleukin-6 (IL-6) gene expression in peripheral blood of depressed patients but did not affect IL-6 levels in healthy volunteers. This selective immunomodulatory effect—normalizing elevated inflammatory markers in disease states without disrupting normal immune function—demonstrates Selank's adaptogenic properties and suggests potential therapeutic applications in conditions characterized by immune dysregulation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe combined immunomodulatory and antiviral properties of Selank, along with its ability to reduce pro-inflammatory cytokines while supporting appropriate immune responses, distinguish it from conventional immunosuppressive or immunostimulatory drugs. The peptide's balanced approach to immune system regulation—enhancing antiviral defenses through IFN-α induction while modulating inflammatory responses—provides a unique therapeutic profile for managing conditions involving both immune dysfunction and inflammation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc space-y-2.5 pl-7\"\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eErshov FI, et al. \"Antiviral activity of immunomodulator Selank in experimental influenza infection.\" Vopr Virusol. 2009;54(5):19-24.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/19882898\/\" class=\"underline\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/19882898\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eKolomin TA, et al. \"Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank.\" Immunobiology. 2011;216(9):998-1003.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0167011511000863\" class=\"underline\"\u003ehttps:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0167011511000863\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eKolomin TA, et al. \"The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action.\" Immunobiology. 2013;218(11):1407-1413.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0161589013005440\" class=\"underline\"\u003ehttps:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0161589013005440\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eAndreeva LA, et al. \"Antiviral properties of structural fragments of the peptide Selank.\" Bioorg Khim. 2010;36(2):272-276.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20506839\/\" class=\"underline\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/20506839\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"research-disclaimer\"\u003e\u003cem\u003e\u003cstrong\u003eDisclaimer:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eThe research articles listed above are for informational purposes only. This product is intended for research use only and not for human or veterinary use.\u003c\/em\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv data-e-type=\"container\" data-element_type=\"container\" data-id=\"c8b3f0a\" class=\"wd-negative-gap elementor-element elementor-element-c8b3f0a e-flex e-con-boxed e-con e-parent e-lazyloaded\"\u003e\n\u003cdiv class=\"e-con-inner\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/main\u003e\u003c\/div\u003e\n\u003cdiv class=\"wd-prefooter\"\u003e\n\u003cdiv class=\"container wd-entry-content\"\u003e⊗PRODUCTS ARE INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly prohibited by law. Products should only be handled by licensed, qualified professionals. Products sold are not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food, or cosmetic.\u003c\/div\u003e\n\u003c\/div\u003e","brand":"CHEATCODES","offers":[{"title":"5mg","offer_id":44420747001971,"sku":null,"price":29.99,"currency_code":"USD","in_stock":true},{"title":"10mg","offer_id":44420747034739,"sku":null,"price":49.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0681\/2316\/4787\/files\/selank_10mg_9afaad74-0a56-4ff1-a97d-d297ab0ac324.jpg?v=1775962589"},{"product_id":"tesamorelin","title":"Tesamorelin","description":"\u003cdiv class=\"wd-page-content main-page-wrapper\"\u003e\u003cmain role=\"main\" class=\"wd-content-layout content-layout-wrapper wd-builder-off\" id=\"main-content\"\u003e\n\u003cdiv role=\"main\" id=\"content\" class=\"site-content col-lg-12\"\u003e\n\u003cdiv class=\"container\"\u003e\n\u003cdiv class=\"row\"\u003e\n\u003cdiv class=\"content-area col-sm-12\"\u003e\n\u003cdiv class=\"elementor elementor-6554\" data-elementor-id=\"6554\" data-elementor-type=\"page\"\u003e\n\u003cdiv data-e-type=\"container\" data-element_type=\"container\" data-id=\"e081ffd\" class=\"wd-negative-gap elementor-element elementor-element-e081ffd e-flex e-con-boxed e-con e-parent e-lazyloaded\"\u003e\n\u003cdiv class=\"e-con-inner\"\u003e\n\u003cdiv data-e-type=\"container\" data-element_type=\"container\" data-id=\"a465110\" class=\"elementor-element elementor-element-a465110 e-con-full e-flex e-con e-child\"\u003e\n\u003cdiv data-widget_type=\"kbpb-product-tabs-advanced.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"68951fc\" class=\"elementor-element elementor-element-68951fc elementor-widget elementor-widget-kbpb-product-tabs-advanced\"\u003e\n\u003cdiv class=\"elementor-widget-container\"\u003e\n\u003cdiv class=\"kbpb-product-tabs-advanced\"\u003e\n\u003cdiv class=\"kbpb-tabs-content\"\u003e\n\u003cdiv id=\"tab-0\" class=\"kbpb-tab-pane active\"\u003e\n\u003cdiv class=\"kbpb-sections-content\"\u003e\n\u003cdiv id=\"section-what-is-tesamorelin\" class=\"kbpb-section\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eWhat is Tesamorelin?\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eTesamorelin is a synthetic peptide analog of growth hormone–releasing hormone (GHRH) that functions as a receptor agonist within the growth hormone–releasing hormone receptor (GHRHR) signaling pathway [1]. Structurally derived from the endogenous human GHRH sequence, the peptide is engineered to interact with native receptor systems involved in hypothalamic–pituitary signaling and growth hormone regulation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eChemically, tesamorelin is the acetate salt of N-[trans-3-hexenoyl]-human GHRH (1–44) amide, consisting of a 44–amino acid peptide sequence that incorporates modifications at the N-terminal region. These structural changes increase resistance to enzymatic degradation, particularly from dipeptidyl aminopeptidase enzymes, allowing the peptide to maintain stability and receptor interaction during experimental studies. Compared with endogenous GHRH, tesamorelin demonstrates improved molecular persistence while preserving high receptor binding affinity and signaling activity in controlled research systems.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eMechanistically, tesamorelin binds to growth hormone–releasing hormone receptors located on somatotroph cells in the anterior pituitary. Activation of these receptors initiates intracellular signaling cascades that regulate growth hormone secretion and downstream endocrine signaling pathways. In biological systems, this process ultimately leads to increased production of insulin-like growth factor-1 (IGF-1) in hepatic and peripheral tissues, a key mediator involved in growth hormone–associated metabolic signaling networks.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eClinical pharmacology research has examined tesamorelin in studies involving endocrine regulation, metabolic signaling, and body composition. Investigations have reported changes in visceral adipose tissue distribution, lipid metabolism, and metabolic markers while maintaining physiological growth hormone pulsatility and feedback regulation through the IGF-1 axis. Additional research has explored tesamorelin within experimental models studying neuroendocrine signaling, metabolic regulation, and endocrine pathway dynamics [1][2][3].\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eFor laboratory research applications, peptide purity and structural integrity are essential for reproducible receptor signaling experiments. Tesamorelin supplied by New England Biologics is produced using controlled solid-phase peptide synthesis (SPPS), followed by purification through high-performance liquid chromatography (HPLC) to isolate the target peptide sequence and remove synthesis byproducts or truncated fragments. Analytical verification procedures, including chromatographic purity profiling and mass spectrometry identity confirmation, are used to verify peptide identity, purity, and batch consistency.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eEach production lot is evaluated to support consistent physicochemical properties such as solubility, structural stability, and reproducibility during laboratory preparation and experimental workflows. Certificates of Analysis describing analytical testing and batch verification are available to support rigorous biochemical and receptor signaling studies.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eTesamorelin supplied by New England Biologics is intended strictly for laboratory research use and is not approved for human or veterinary applications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"section-tesamorelin-chemical-identity\" class=\"kbpb-section\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eTesamorelin Chemical Identity\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eTesamorelin is a synthetic peptide analog of growth hormone–releasing hormone (GHRH) composed of a 44–amino acid sequence derived from the N-terminal region of endogenous human GHRH. The peptide retains the receptor-binding domains necessary for interaction with the growth hormone–releasing hormone receptor (GHRHR) while incorporating sequence modifications that enhance resistance to enzymatic degradation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThese structural adjustments help maintain conformational stability during experimental assays. As a GHRH receptor agonist peptide, Tesamorelin enables controlled investigation of hypothalamic–pituitary signaling mechanisms and peptide–receptor interactions in biochemical and cellular research systems.\u003c\/p\u003e\n\u003cdiv class=\"peptide-structure-content\"\u003e\n\u003cdiv class=\"structure-images\"\u003e\n\u003cdiv class=\"structure-2d\"\u003e\n\u003ch3\u003e\u003cb\u003eTesamorelin 2D Structure\u003c\/b\u003e\u003c\/h3\u003e\n\u003cimg alt=\"Tesamorelin 2D Structure\" src=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/image\/imgsrv.fcgi?cid=44147413\u0026amp;t=l\" class=\"peptide-structure-image\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"structure-3d\"\u003e\n\u003ch3\u003e\u003cb\u003eTesamorelin 3D Structure\u003c\/b\u003e\u003c\/h3\u003e\n\u003cimg alt=\"Tesamorelin 3D Structure\" src=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/image\/imgsrv.fcgi?cid=44147413\u0026amp;t=l\u0026amp;3d=true\" class=\"peptide-structure-image\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"chemical-properties\"\u003e\n\u003ch3\u003e\u003cb\u003eChemical Properties and Registry Information for Tesamorelin\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe following chemical identifiers describe the molecular composition and registry information associated with this compound for laboratory research.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cb\u003eProperty\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cb\u003eInformation\u003c\/b\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cb\u003eName \u0026amp; Synonyms\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eTesamorelin; Tesamorelin acetate; Growth Hormone–Releasing Hormone Analog\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cb\u003ePubChem CID\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/44147413\"\u003e\u003cspan\u003e44147413\u003c\/span\u003e\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cb\u003eCAS Number\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003e901758-09-6\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cb\u003eMolecular Formula\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cspan\u003eC\u003c\/span\u003e\u003cspan\u003e223\u003c\/span\u003e\u003cspan\u003eH\u003c\/span\u003e\u003cspan\u003e370\u003c\/span\u003e\u003cspan\u003eN\u003c\/span\u003e\u003cspan\u003e72\u003c\/span\u003e\u003cspan\u003eO\u003c\/span\u003e\u003cspan\u003e69\u003c\/span\u003e\u003cspan\u003eS\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cb\u003eMolecular Weight\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003e5196 g\/mol\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cb\u003ePeptide Length\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003e44 amino acids\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cb\u003eCompound Class\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eSynthetic peptide; GHRH receptor agonist\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cb\u003ePrimary Targets\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eGrowth hormone–releasing hormone receptor (GHRHR)\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cb\u003eSequence\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eYADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cb\u003eInChIKey\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eLAJZPRPPHHRDIK-BCEXXFMNSA-N\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr class=\"iupac-row\"\u003e\n\u003cth\u003eIUPAC Name\u003c\/th\u003e\n\u003ctd\u003e\n\u003cdiv class=\"iupac-collapsible\"\u003e\n\u003cbutton type=\"button\" class=\"iupac-toggle-btn\"\u003e\u003cspan class=\"toggle-text\"\u003eShow IUPAC Name\u003c\/span\u003e\u003cspan class=\"toggle-icon\"\u003e▼\u003c\/span\u003e\u003c\/button\u003e\n\u003cdiv class=\"iupac-content\"\u003eacetic acid;(4S)-4-[[2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(E)-hex-3-enoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-3-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eTesamorelin retains the receptor-binding domain of endogenous growth hormone–releasing hormone while incorporating structural modifications that enhance resistance to enzymatic degradation compared with native GHRH. This increased stability allows the peptide to maintain receptor interaction in experimental systems for longer durations, making Tesamorelin useful in laboratory models investigating GHRH receptor signaling, peptide–receptor dynamics, and endocrine regulatory pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"section-tesamorelin-research-applications\" class=\"kbpb-section\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eTesamorelin Research Applications\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eTesamorelin is used in laboratory and translational research as a peptide tool for studying growth hormone–releasing hormone receptor signaling, endocrine feedback dynamics, and downstream metabolic pathway regulation. Because it is a stabilized GHRH analog with defined receptor activity, Tesamorelin is especially useful in experimental models that examine how peptide-mediated signaling influences growth hormone pulsatility, lipid handling, hepatic metabolism, and cross-tissue endocrine communication.\u003c\/p\u003e\n\u003ch3\u003eVisceral Fat Biology and Metabolic Signaling\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eTesamorelin is widely studied in metabolic research for its effects on visceral adipose tissue biology and endocrine signaling related to body composition. Because it functions as a growth hormone–releasing hormone (GHRH) receptor agonist, tesamorelin stimulates endogenous growth hormone signaling, which in turn influences lipid metabolism and adipose tissue regulation. Experimental and translational studies have examined how activation of the growth hormone axis alters fat distribution, particularly within visceral adipose depots that are strongly associated with metabolic health markers [4].\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eResearch models have repeatedly demonstrated that tesamorelin exposure is associated with measurable reductions in visceral adipose tissue while largely preserving subcutaneous fat stores. These studies often evaluate parameters such as trunk fat distribution, waist circumference, and metabolic biomarkers to understand how endocrine signaling affects fat metabolism and energy regulation [4].\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eAdditional investigations examining liver fat metabolism reported that changes in visceral adiposity during tesamorelin exposure may correspond with reductions in hepatic lipid accumulation. In randomized clinical research involving individuals with abdominal fat accumulation, tesamorelin was associated with measurable decreases in liver fat content alongside reductions in visceral adipose tissue, supporting the concept that endocrine signaling can influence ectopic fat deposition across organs [5].\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eBecause visceral fat plays a key role in metabolic signaling, inflammatory pathways, and lipid transport through the portal circulation, tesamorelin has become a useful experimental compound for researchers studying how endocrine signaling affects fat metabolism, adipose tissue function, and cross-tissue metabolic communication.\u003c\/p\u003e\n\u003ch3\u003eSkeletal Muscle Mass and Body Composition\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eBeyond adipose biology, tesamorelin has been investigated in research models examining skeletal muscle composition and muscle quality. In clinical imaging studies evaluating trunk musculature, tesamorelin exposure was associated with increases in muscle area and reductions in intramuscular fat infiltration, suggesting changes in muscle composition linked to growth hormone–mediated metabolic signaling [1].\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThese studies frequently measure skeletal muscle density and cross-sectional muscle area using imaging techniques such as computed tomography. Improvements in muscle density are particularly relevant because lower muscle density is often associated with higher intramuscular fat content and reduced metabolic efficiency. Observations from these studies indicate that modulation of the growth hormone–IGF-1 axis through GHRH receptor stimulation may influence both muscle tissue composition and broader body composition signaling [1].\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eResearch programs examining tesamorelin in this context often explore how endocrine signaling affects lean muscle regulation, protein metabolism, and interactions between muscle tissue and metabolic pathways. As a result, the peptide has been incorporated into experimental models focused on body composition, muscle metabolism, and the relationship between hormone signaling and musculoskeletal physiology.\u003c\/p\u003e\n\u003ch3\u003eCardiovascular and Metabolic Risk Markers\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eTesamorelin research has also explored how changes in visceral adiposity influence metabolic and cardiovascular risk markers. Because visceral adipose tissue is closely linked to lipid metabolism and systemic inflammation, studies examining endocrine modulation of this tissue often track related metabolic indicators.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eExperimental analyses evaluating growth hormone–releasing hormone signaling have reported associations between reductions in visceral adiposity and improvements in metabolic parameters such as lipid profiles and inflammatory markers. Research reviews examining the broader metabolic effects of GHRH analog signaling highlight its potential influence on triglyceride metabolism, cholesterol balance, and cardiovascular risk indicators through downstream endocrine pathways [4].\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eIn laboratory and translational research settings, tesamorelin is therefore used as a tool for studying the relationship between endocrine signaling, adipose tissue biology, and cardiovascular metabolic markers. These models help investigators explore how hormonal regulation of fat distribution may influence broader metabolic health pathways.\u003c\/p\u003e\n\u003ch3\u003eCognitive Function and Neuroendocrine Signaling\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eTesamorelin has also attracted research interest in studies examining neuroendocrine signaling and cognitive biology. Growth hormone and insulin-like growth factor-1 (IGF-1) pathways are known to play roles in brain metabolism, neuronal signaling, and neuroplasticity, leading researchers to investigate whether modulation of these pathways influences cognitive processes.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eExperimental studies evaluating endocrine signaling in aging populations have explored how stimulation of the GHRH pathway affects cognitive performance, memory-related processes, and neurochemical signaling patterns. In these research contexts, investigators often measure cognitive test performance, brain imaging markers, and neurochemical indicators associated with neuronal metabolism and signaling activity.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eBecause tesamorelin activates upstream components of the growth hormone axis while preserving physiological feedback regulation, it provides a useful experimental model for studying how endocrine signaling interacts with neural systems involved in cognition, energy metabolism, and aging-related biological processes.\u003c\/p\u003e\n\u003ch3\u003eGlucose Metabolism and Endocrine Regulation\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eAnother important research area involving tesamorelin focuses on glucose metabolism and insulin signaling. Growth hormone activity is closely connected to carbohydrate metabolism, making it important for researchers to understand how modulation of the growth hormone axis influences glucose regulation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eControlled clinical studies examining tesamorelin exposure in individuals with metabolic conditions have evaluated markers such as fasting glucose, insulin levels, and hemoglobin A1c to assess the peptide's effects on glucose homeostasis. Findings from these investigations indicate that tesamorelin can increase circulating IGF-1 levels while maintaining stable glucose control parameters in studied populations [3].\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThese results are particularly relevant for researchers investigating endocrine feedback systems, as the GHRH-growth hormone-IGF-1 axis involves complex regulatory mechanisms that influence both lipid and carbohydrate metabolism. Tesamorelin therefore provides a useful model compound for studying how peptide receptor signaling interacts with metabolic pathways governing energy balance and hormone regulation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"section-how-tesamorelin-works-mechanism-of-action\" class=\"kbpb-section\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eHow Tesamorelin Works (Mechanism of Action)\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eTesamorelin is a synthetic peptide analog of growth hormone–releasing hormone that functions as an agonist of the growth hormone–releasing hormone receptor (GHRHR). In laboratory systems, the peptide is used to investigate receptor-mediated endocrine signaling and the regulatory pathways associated with growth hormone release.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eBy interacting with the GHRH receptor expressed on pituitary somatotroph cells, Tesamorelin modulates intracellular signaling cascades that influence growth hormone secretion dynamics and downstream metabolic signaling networks in experimental models.\u003c\/p\u003e\n\u003ch3\u003eTarget Engagement\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eTesamorelin engages the growth hormone–releasing hormone receptor, a class B G protein-coupled receptor located primarily on somatotroph cells of the anterior pituitary in vertebrate endocrine systems [1]. The peptide retains the key receptor-binding region of endogenous GHRH, allowing it to interact with the extracellular domain of the receptor with high specificity.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eStructural studies indicate that peptide binding stabilizes the receptor in an active conformation, enabling coupling to Gs proteins and initiating downstream signaling processes. Compared with native GHRH, Tesamorelin incorporates sequence modifications that improve resistance to proteolytic degradation, allowing sustained receptor engagement in biochemical assays and experimental models. These properties make Tesamorelin useful for examining ligand–receptor dynamics and the pharmacology of peptide agonists that target the GHRH signaling system.\u003c\/p\u003e\n\u003ch3\u003eDownstream Signaling Pathways\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eActivation of the GHRH receptor by Tesamorelin primarily triggers the cyclic AMP signaling pathway through Gs protein coupling. Following receptor activation, adenylate cyclase activity increases intracellular cyclic AMP concentrations, which in turn activates protein kinase A. Protein kinase A phosphorylation events regulate transcription factors and intracellular proteins involved in hormone secretion and endocrine signaling regulation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eLaboratory investigations also report downstream activation of pathways linked to calcium mobilization and vesicle-mediated hormone release from secretory granules. Through these signaling cascades, Tesamorelin provides a controlled experimental model for studying cyclic AMP–dependent endocrine signaling, kinase activation, and peptide-mediated receptor signaling within hypothalamic–pituitary regulatory networks [7].\u003c\/p\u003e\n\u003ch3\u003eCellular Effects in Experimental Models\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eIn experimental systems, Tesamorelin exposure has been associated with measurable changes in endocrine signaling markers and metabolic pathway indicators. Biochemical assays demonstrate increased cyclic AMP production and enhanced activity of signaling proteins downstream of GHRH receptor activation. In cellular and animal models, investigators often measure changes in growth hormone secretion patterns, insulin-like growth factor signaling markers, and metabolic biomarkers associated with lipid and energy metabolism [3].\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eMechanistic investigations also examine gene expression profiles related to hormone signaling, lipid mobilization pathways, and hepatic metabolic processes. Collectively, these experimental observations position Tesamorelin as a useful research peptide for studying receptor-mediated endocrine signaling and the broader metabolic pathways influenced by growth hormone regulatory systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"section-tesamorelin-comparison-to-related-research-compounds\" class=\"kbpb-section\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eTesamorelin Comparison to Related Research Compounds\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eTesamorelin is part of a broader class of peptide molecules used to investigate endocrine signaling and metabolic regulation. Within laboratory research, it is often compared with other peptides that influence growth hormone pathways or downstream metabolic signaling.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eTwo commonly referenced compounds in this research area are Sermorelin and Ipamorelin, both of which interact with regulatory systems that control growth hormone signaling but through distinct receptor mechanisms.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eProperty\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eTesamorelin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/cheatcodespeptides.com\/products\/tesamorelin\"\u003e\n\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eType\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eSynthetic peptide analog of growth hormone–releasing hormone\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eSynthetic peptide fragment of GHRH\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eSynthetic pentapeptide growth hormone secretagogue\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePrimary Target\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eGrowth hormone–releasing hormone receptor (GHRHR)\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eGrowth hormone–releasing hormone receptor (GHRHR)\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eGhrelin receptor (GHSR-1a)\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMechanism Summary\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eAgonist that activates GHRHR signaling and stimulates cAMP-dependent endocrine signaling pathways\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eShorter GHRH analog that activates the same receptor but with reduced structural stability\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eSelective ghrelin receptor agonist that stimulates GH signaling through a distinct receptor pathway\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eTypical Research Systems\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eIn vitro receptor assays, endocrine signaling models, metabolic animal models\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eReceptor pharmacology assays, peptide signaling studies, pituitary cell models\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eGhrelin receptor assays, metabolic signaling models, neuroendocrine pathway studies\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMechanistic Focus\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eGrowth hormone axis regulation and endocrine signaling dynamics\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eGHRH receptor signaling and peptide structure function relationships\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eGhrelin receptor signaling and growth hormone secretagogue pathway investigation\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory Category\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eResearch-use peptide supplied for laboratory investigation\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eResearch-use peptide supplied for laboratory investigation\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eResearch-use peptide supplied for laboratory investigation\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eResearch Stage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eReceptor pharmacology research and metabolic signaling studies\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003eReceptor signaling assays and endocrine pathway research\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan\u003ePreclinical receptor signaling and metabolic pathway investigation\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eAlthough Tesamorelin and Sermorelin both act on the growth hormone–releasing hormone receptor, Tesamorelin incorporates structural modifications that increase stability and resistance to enzymatic degradation compared with the shorter Sermorelin fragment. This improved stability allows researchers to examine receptor activation and downstream signaling with a peptide that maintains activity for longer durations in experimental systems.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eIpamorelin differs mechanistically because it targets the ghrelin receptor rather than the GHRH receptor. As a result, it activates growth hormone signaling through an alternative endocrine pathway. Comparing Tesamorelin with ghrelin receptor agonists such as Ipamorelin allows investigators to explore how distinct receptor systems converge on similar hormonal signaling outputs while using different upstream molecular mechanisms.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eRelated compounds that investigate growth hormone signaling and peptide receptor pharmacology may also be available within the New England Biologics catalog to support endocrine pathway research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"section-tesamorelin-lab-safety-handling-guidelines\" class=\"kbpb-section\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eTesamorelin Lab Safety \u0026amp; Handling Guidelines\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eTesamorelin should be handled only by qualified researchers following standard chemical and biochemical safety procedures. The compound is typically supplied as a lyophilized peptide to support stability during storage and transport.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eFor long term preservation of peptide integrity, lyophilized Tesamorelin should be stored at −4 °F (−20 °C) or below in a sealed container protected from moisture, heat, and direct light. Maintaining controlled storage conditions helps preserve peptide structure, reduce degradation risk, and maintain analytical purity for laboratory research applications.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eAfter reconstitution, Tesamorelin peptide solutions are typically stored at 36–46 °F (2–8 °C). Careful handling and temperature control help reduce degradation processes such as hydrolysis, oxidation, and peptide aggregation that may influence experimental reproducibility in biochemical assays or cellular research systems.\u003c\/p\u003e\n\u003ch3\u003eHandling Guidelines\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eProper storage and handling of lyophilized Tesamorelin helps preserve peptide stability and ensures consistent performance in receptor signaling studies, metabolic pathway assays, and other laboratory investigations. Researchers working with Tesamorelin should follow standard peptide handling practices designed to protect the compound from environmental stress and contamination.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eStore lyophilized Tesamorelin at −4 °F (−20 °C) or below in a dry, sealed environment\u003c\/li\u003e\n\u003cli\u003eAllow the vial to reach room temperature before opening to prevent moisture condensation\u003c\/li\u003e\n\u003cli\u003eProtect the peptide from prolonged exposure to light, heat, and humidity\u003c\/li\u003e\n\u003cli\u003eUse sterile laboratory equipment and preparation techniques when handling the material\u003c\/li\u003e\n\u003cli\u003eAvoid repeated freeze–thaw cycles that may reduce peptide stability\u003c\/li\u003e\n\u003cli\u003eClearly label reconstituted solutions with preparation date and concentration for laboratory reference\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eReconstitution Guidelines\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eCorrect peptide reconstitution is important for maintaining Tesamorelin stability and ensuring accurate experimental preparation. Researchers typically dissolve lyophilized peptides under controlled laboratory conditions to support consistent concentration and solubility for biochemical assays and signaling pathway studies.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReconstitute Tesamorelin using sterile bacteriostatic water or an appropriate laboratory buffer\u003c\/li\u003e\n\u003cli\u003eIntroduce solvent slowly along the interior wall of the vial to reduce foaming\u003c\/li\u003e\n\u003cli\u003eAvoid vigorous shaking or vortexing during preparation\u003c\/li\u003e\n\u003cli\u003eGently swirl or invert the vial until the peptide is fully dissolved\u003c\/li\u003e\n\u003cli\u003eStore reconstituted solutions at 36–46 °F (2–8 °C) under controlled laboratory conditions\u003c\/li\u003e\n\u003cli\u003ePrepare aliquots when appropriate to reduce repeated freeze–thaw exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eLaboratory Safety Protocols\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eStandard laboratory safety practices should always be followed when working with research peptides such as Tesamorelin. Appropriate protective equipment and safe laboratory procedures help reduce exposure risk and support responsible handling of biochemical research materials.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eWear appropriate personal protective equipment including gloves, lab coat, and protective eyewear\u003c\/li\u003e\n\u003cli\u003eHandle Tesamorelin within approved laboratory workspaces using standard safety practices\u003c\/li\u003e\n\u003cli\u003eAvoid inhalation, ingestion, or direct contact with the compound\u003c\/li\u003e\n\u003cli\u003eDispose of unused material and preparation supplies according to institutional chemical waste procedures\u003c\/li\u003e\n\u003cli\u003eMaintain proper labeling, storage records, and documentation for all research compounds\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eFollowing these Tesamorelin handling and safety guidelines helps preserve peptide integrity while supporting safe laboratory practices and reliable experimental results.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eAll Tesamorelin products supplied by New England Biologics are intended strictly for laboratory research and development use only and are not approved for human or veterinary use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"section-frequently-asked-questions\" class=\"kbpb-section\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e\n\u003ch3\u003eIs tesamorelin approved for human use?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eNo. Tesamorelin supplied by New England Biologics is not approved for human or veterinary use and is provided strictly as a laboratory research compound. A pharmaceutical product containing tesamorelin as an active ingredient, marketed under the brand name Egrifta, has received regulatory approval in certain jurisdictions for specific medical indications, but this approval applies only to the regulated drug product and does not apply to tesamorelin peptides.\u003c\/p\u003e\n\u003ch3\u003eWhere can researchers obtain high purity tesamorelin?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eResearchers seeking high purity tesamorelin for laboratory studies may obtain the peptide from specialized research reagent suppliers such as New England Biologics. Tesamorelin produced by CHEAT CODES is synthesized using controlled solid phase peptide synthesis and purified through HPLC methods. Analytical verification and Certificates of Analysis are provided to confirm peptide identity, purity, and batch consistency for laboratory research applications.\u003c\/p\u003e\n\u003ch3\u003eWhat is tesamorelin used for in research?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eTesamorelin is used in laboratory research to study growth hormone releasing hormone receptor signaling and its downstream effects on metabolic and endocrine pathways. In experimental systems such as receptor assays, cell culture models, and metabolic animal studies, researchers investigate how tesamorelin influences cyclic AMP signaling, growth hormone axis regulation, lipid metabolism pathways, and visceral fat biology. These studies help scientists explore mechanisms involved in metabolic signaling, endocrine communication between tissues, and energy regulation in controlled experimental models.\u003c\/p\u003e\n\u003ch3\u003eHow should tesamorelin be stored in laboratory environments?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eFor long term stability, lyophilized tesamorelin is typically stored at −4 °F (−20 °C) or below in a sealed container protected from light, heat, and moisture. After reconstitution, peptide solutions are generally stored at 36–46 °F (2–8 °C). Maintaining controlled storage conditions helps preserve peptide structure, reduce degradation processes, and support reproducibility in receptor signaling and biochemical research systems.\u003c\/p\u003e\n\u003ch3\u003eHow long does it take to ship tesamorelin in the United States?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eOrders placed with New England Biologics are generally processed within one to two business days after payment confirmation. Domestic shipments within the United States are typically delivered within several business days depending on carrier service and destination. Shipping timelines may vary based on order volume, logistics conditions, and selected shipping options.\u003c\/p\u003e\n\u003ch3\u003eDoes New England Biologics ship research peptides internationally?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eYes. New England Biologics ships research compounds to many international destinations. International shipping availability may depend on the destination country and applicable import regulations. Researchers are responsible for ensuring compliance with local import requirements and regulations governing laboratory research materials. Detailed information regarding shipping options and payment methods is available through the New England Biologics shipping and payments policy.\u003c\/p\u003e\n\u003ch3\u003eWhat effects is tesamorelin studied for in research?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eIn research settings, tesamorelin is often studied for its role in growth hormone signaling and how that signaling may influence body composition. Laboratory and clinical studies have examined how the peptide affects processes related to visceral fat metabolism, lean muscle mass regulation, and metabolic activity. These experimental models help researchers explore how growth hormone–related pathways may influence fat distribution, muscle tissue maintenance, and broader metabolic signaling.\u003c\/p\u003e\n\u003ch3\u003eWhat research applications are commonly associated with tesamorelin?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eTesamorelin is commonly used in studies investigating hormone signaling and metabolic health. Researchers examine how the peptide interacts with growth hormone pathways that are linked to fat metabolism, body composition, and energy regulation. Experimental models may explore topics such as visceral fat reduction mechanisms, lean muscle signaling, and metabolic pathway activity to better understand how peptide-driven hormone signals influence these biological processes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"section-regulatory-legal-u-s\" class=\"kbpb-section\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eRegulatory \u0026amp; Legal (U.S.)\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eAll products supplied by New England Biologics are intended strictly for research and development use. These materials are provided for laboratory investigation and scientific experimentation and are not supplied for use in humans or animals.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThis product is not a drug, food, dietary supplement, medical device, or cosmetic. It has not been approved by the U.S. Food and Drug Administration (FDA) for medical, diagnostic, or therapeutic use. Any statements regarding the compound are derived from published scientific literature and have not been evaluated by the FDA. These materials are not intended to diagnose, treat, cure, or prevent any disease.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eMaterials supplied by New England Biologics must be handled only by qualified professionals trained in laboratory research procedures. The introduction of this product into humans or animals is strictly prohibited and may violate applicable laws and regulations.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eResearchers and institutions are responsible for ensuring that the purchase, handling, storage, use, and disposal of research materials comply with all applicable federal, state, and local regulations, as well as institutional policies governing laboratory research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"section-sources-references\" class=\"kbpb-section\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eSources \u0026amp; References\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e1. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV, Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM, Journal of Frailty \u0026amp; Aging (2019, 8(3):154–159). Link:\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6766405\/\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6766405\/\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e2. Structural basis for activation of the growth hormone-releasing hormone receptor, Zhou F, Zhang H, Cong Z et al., Nature Communications (2020, 11:5205). Link:\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/doi.org\/10.1038\/s41467-020-18945-0\"\u003ehttps:\/\/doi.org\/10.1038\/s41467-020-18945-0\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e3. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial, Clemmons DR, Miller S, Mamputu JC, PLoS One (2017, 12(6):e0179538). Link:\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/doi.org\/10.1371\/journal.pone.0179538\"\u003ehttps:\/\/doi.org\/10.1371\/journal.pone.0179538\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e4. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies, Stanley TL, Grinspoon SK, Growth Hormone \u0026amp; IGF Research (2015, 25(2):59–65). Link:\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/doi.org\/10.1016\/j.ghir.2014.12.005\"\u003ehttps:\/\/doi.org\/10.1016\/j.ghir.2014.12.005\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e5. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial, Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK, JAMA (2014, 312(4):380–389). Link:\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/doi.org\/10.1001\/jama.2014.8334\"\u003ehttps:\/\/doi.org\/10.1001\/jama.2014.8334\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e6. Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease, Stanley TL, Fourman LT, Wong LP, Sadreyev R, Billingsley JM, Feldpausch MN, Zheng I, Pan CS, Boutin A, Lee H, Corey KE, Torriani M, Kleiner DE, Chung RT, Hadigan CM, Grinspoon SK, Clinical Infectious Diseases (2021, 73(4):621–630). Link:\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/doi.org\/10.1093\/cid\/ciab019\"\u003ehttps:\/\/doi.org\/10.1093\/cid\/ciab019\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e7. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling, Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV, Reviews in Endocrine and Metabolic Disorders (2025, 26(3):343–352). Link:\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/doi.org\/10.1007\/s11154-025-09952-x\"\u003ehttps:\/\/doi.org\/10.1007\/s11154-025-09952-x\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv data-e-type=\"container\" data-element_type=\"container\" data-id=\"c8b3f0a\" class=\"wd-negative-gap elementor-element elementor-element-c8b3f0a e-flex e-con-boxed e-con e-parent e-lazyloaded\"\u003e\n\u003cdiv class=\"e-con-inner\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/main\u003e\u003c\/div\u003e\n\u003cdiv class=\"wd-prefooter\"\u003e\n\u003cdiv class=\"container wd-entry-content\"\u003e⊗PRODUCTS ARE INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly prohibited by law. Products should only be handled by licensed, qualified professionals. Products sold are not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food, or cosmetic.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan data-sheets-root=\"1\"\u003e\u003cbr\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"CHEATCODES","offers":[{"title":"5mg","offer_id":44420746150003,"sku":null,"price":49.99,"currency_code":"USD","in_stock":true},{"title":"10mg","offer_id":44420746182771,"sku":null,"price":99.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0681\/2316\/4787\/files\/tesamorelin_5mg.jpg?v=1775966081"},{"product_id":"cjc-1295-ipa","title":"CJC 1295 + IPA","description":"\u003cdiv class=\"kbpb-section\" id=\"section-what-is-cjc-1295-no-dac-ipamorelin\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eWhat is CJC-1295 (No DAC) + Ipamorelin?\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eCJC-1295 (No DAC) + Ipamorelin is a synergistic peptide combination that optimizes growth hormone secretion through dual mechanisms of action. This blend pairs a growth hormone-releasing hormone (GHRH) analog with a selective growth hormone-releasing peptide (GHRP), working together to stimulate the body's natural production and release of growth hormone in a physiological, pulsatile manner.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eCJC-1295 (No DAC)\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eis a modified analog of growth hormone-releasing hormone consisting of 29 amino acids. The \"no DAC\" designation indicates the absence of Drug Affinity Complex, resulting in a relatively short half-life of approximately 30 minutes. This shorter duration allows for more frequent administration and precise control over GH pulse timing, mimicking the body's natural secretion patterns. CJC-1295 works by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland, directly stimulating both the synthesis and release of growth hormone. Clinical studies demonstrate that CJC-1295 administration results in dose-dependent increases in plasma GH concentrations by 2- to 10-fold for extended periods, with corresponding increases in IGF-1 levels.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eIpamorelin\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eis a selective pentapeptide growth hormone secretagogue composed of five amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2). Originally developed by Novo Nordisk, ipamorelin is distinguished as the first selective GHRP with minimal effects on secondary hormone pathways. Unlike other growth hormone-releasing peptides, ipamorelin does not significantly affect cortisol, prolactin, or acetylcholine levels, making it one of the safest and most targeted GH secretagogues available. Ipamorelin functions by binding to and activating ghrelin receptors (GHS-R1a) on pituitary cells, triggering GH release through pathways distinct from GHRH.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eSynergistic Mechanism\u003c\/strong\u003e: When combined, CJC-1295 (no DAC) and Ipamorelin work through complementary pathways to produce synergistic effects on growth hormone secretion. CJC-1295 stimulates GH production and release through cAMP-dependent pathways, while Ipamorelin activates ghrelin receptors to increase intracellular calcium and enhance GH release. Research demonstrates that concurrent administration of GHRH analogs with GHRPs results in significantly higher peak GH levels and greater total GH output compared to either compound administered alone. Studies show that the combination can produce GH responses 130% or greater than individual peptides, with enhanced frequency and amplitude of natural GH pulses.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThis synergistic relationship is particularly valuable because it allows for lower doses of each peptide while achieving superior results, minimizing potential side effects while maximizing therapeutic benefits. The combination preserves the pulsatile nature of GH secretion, which is critical for optimal physiological effects, as continuous GH elevation can lead to receptor desensitization.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe downstream effects of enhanced GH secretion include increased production of insulin-like growth factor-1 (IGF-1), which mediates many of growth hormone's anabolic effects. IGF-1 promotes protein synthesis, enhances glucose uptake in skeletal muscle, stimulates lipolysis in adipose tissue, and plays crucial roles in tissue repair and regeneration. The CJC-1295 + Ipamorelin combination thus represents a sophisticated approach to optimizing the GH\/IGF-1 axis for improved body composition, metabolic health, and physical performance.\u003c\/p\u003e\n \n\u003ch4\u003ePurity \u0026amp; Quality\u003c\/h4\u003e\nOur blend is provided at research-grade purity, suitable for laboratory applications and experimental protocols. Each batch undergoes quality control testing to ensure consistency and reliability for your research needs.\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eImportant:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eThis product is intended for research purposes only and is not for human or veterinary use. It is sold for laboratory and scientific investigation only.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"kbpb-section\" id=\"section-cjc-1295-structure\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eCJC 1295 Structure\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e \n\u003cdiv class=\"peptide-structure-content\"\u003e\n\u003ch3\u003eChemical Structure\u003c\/h3\u003e\n\u003cdiv class=\"structure-images\"\u003e\n\u003cdiv class=\"structure-2d\"\u003e\n\u003ch4\u003e2D Structure\u003c\/h4\u003e\n\u003cimg class=\"peptide-structure-image\" src=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/image\/imgsrv.fcgi?cid=56841945\u0026amp;t=l\" alt=\"CJC 1295 2D Structure\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"structure-3d\"\u003e\n\u003ch4\u003e3D Structure\u003c\/h4\u003e\n\u003cimg class=\"peptide-structure-image\" src=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/image\/imgsrv.fcgi?cid=56841945\u0026amp;t=l\u0026amp;3d=true\" alt=\"CJC 1295 3D Structure\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"chemical-properties\"\u003e\n\u003ch3\u003eChemical Properties\u003c\/h3\u003e\n\u003ctable class=\"peptide-properties-table\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003eCAS Number\u003c\/th\u003e\n\u003ctd\u003e863288-34-0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular Formula\u003c\/th\u003e\n\u003ctd\u003eC152H252N44O42\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular Weight\u003c\/th\u003e\n\u003ctd\u003e3367.9 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr class=\"iupac-row\"\u003e\n\u003cth\u003eIUPAC Name\u003c\/th\u003e\n\u003ctd\u003e\n\u003cdiv class=\"iupac-collapsible\"\u003e\n\u003cbutton class=\"iupac-toggle-btn\" type=\"button\"\u003e\u003cspan class=\"toggle-text\"\u003eShow IUPAC Name\u003c\/span\u003e\u003cspan class=\"toggle-icon\"\u003e▼\u003c\/span\u003e\u003c\/button\u003e\n\u003cdiv class=\"iupac-content\"\u003e(3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eInChIKey\u003c\/th\u003e\n\u003ctd\u003e\u003ccode\u003eXOZMWINMZMMOBR-HRDSVTNWSA-N\u003c\/code\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp class=\"pubchem-link\"\u003e\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/56841945\" rel=\"noopener noreferrer\" target=\"_blank\"\u003eView full compound data on PubChem →\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"kbpb-section\" id=\"section-ipamorelin-structure\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eIpamorelin Structure\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e \n\u003cdiv class=\"peptide-structure-content\"\u003e\n\u003ch3\u003eChemical Structure\u003c\/h3\u003e\n\u003cdiv class=\"structure-images\"\u003e\n\u003cdiv class=\"structure-2d\"\u003e\n\u003ch4\u003e2D Structure\u003c\/h4\u003e\n\u003cimg class=\"peptide-structure-image\" src=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/image\/imgsrv.fcgi?cid=9831659\u0026amp;t=l\" alt=\"Ipamorelin 2D Structure\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"structure-3d\"\u003e\n\u003ch4\u003e3D Structure\u003c\/h4\u003e\n\u003cimg class=\"peptide-structure-image\" src=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/image\/imgsrv.fcgi?cid=9831659\u0026amp;t=l\u0026amp;3d=true\" alt=\"Ipamorelin 3D Structure\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"chemical-properties\"\u003e\n\u003ch3\u003eChemical Properties\u003c\/h3\u003e\n\u003ctable class=\"peptide-properties-table\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003eCAS Number\u003c\/th\u003e\n\u003ctd\u003e170851-70-4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular Formula\u003c\/th\u003e\n\u003ctd\u003eC38H49N9O5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular Weight\u003c\/th\u003e\n\u003ctd\u003e711.9 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr class=\"iupac-row\"\u003e\n\u003cth\u003eIUPAC Name\u003c\/th\u003e\n\u003ctd\u003e\n\u003cdiv class=\"iupac-collapsible\"\u003e\n\u003cbutton class=\"iupac-toggle-btn\" type=\"button\"\u003e\u003cspan class=\"toggle-text\"\u003eShow IUPAC Name\u003c\/span\u003e\u003cspan class=\"toggle-icon\"\u003e▼\u003c\/span\u003e\u003c\/button\u003e\n\u003cdiv class=\"iupac-content\"\u003e(2S)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[(2-amino-2-methylpropanoyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eInChIKey\u003c\/th\u003e\n\u003ctd\u003e\u003ccode\u003eNEHWBYHLYZGBNO-BVEPWEIPSA-N\u003c\/code\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp class=\"pubchem-link\"\u003e\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/9831659\" rel=\"noopener noreferrer\" target=\"_blank\"\u003eView full compound data on PubChem →\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"kbpb-section\" id=\"section-research-applications\"\u003e\n\u003ch2 class=\"kbpb-section-title\"\u003eResearch Applications\u003c\/h2\u003e\n\u003cdiv class=\"kbpb-section-content\"\u003e\n\u003ch4 class=\"font-claude-response-body-bold text-text-100 mt-1\"\u003eMuscle Development and Protein Synthesis\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe CJC-1295 and Ipamorelin combination promotes lean muscle development through multiple mechanisms mediated by growth hormone and IGF-1. Growth hormone directly and indirectly stimulates protein synthesis while reducing protein breakdown in skeletal muscle tissue. Research demonstrates that GH acts as a primary anabolic hormone during both fed and fasted states, with effects becoming more pronounced during metabolic stress when GH increases protein synthesis and decreases breakdown at the whole-body level.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eStudies show that enhanced GH secretion increases non-oxidative disposal of amino acids, indicating greater incorporation into protein rather than oxidation for energy. GH-induced IGF-1 production further amplifies anabolic effects by activating satellite cells, enhancing muscle fiber regeneration, and promoting cellular pathways essential for muscle hypertrophy. The preservation of lean body mass is particularly evident during periods of caloric restriction or aging, where GH helps maintain muscle tissue while preferentially mobilizing fat stores for energy.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe synergistic effect of combining GHRH analogs with GHRPs creates more robust and sustained GH pulses, which research indicates produces superior outcomes for muscle development compared to single peptide administration. Clinical observations suggest that the combination promotes gradual, sustainable increases in lean muscle mass while supporting recovery from exercise-induced muscle damage. The preserved pulsatile GH pattern closely mimics natural physiological secretion, optimizing receptor sensitivity and maximizing anabolic responses in muscle tissue.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc space-y-2.5 pl-7\"\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eTeichman SL, et al. \"Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.\" Journal of Clinical Endocrinology \u0026amp; Metabolism. 2006;91(3):799-805.\u003cspan\u003e \u003c\/span\u003e\u003ca class=\"underline\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16352683\/\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/16352683\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eRaun K, et al. \"Ipamorelin, the first selective growth hormone secretagogue.\" European Journal of Endocrinology. 1998;139(5):552-561.\u003cspan\u003e \u003c\/span\u003e\u003ca class=\"underline\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9849822\/\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/9849822\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eJørgensen JOL, et al. \"Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects.\" Endocrine Reviews. 2009;30(2):152-177.\u003cspan\u003e \u003c\/span\u003e\u003ca class=\"underline\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/19240267\/\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/19240267\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"font-claude-response-body-bold text-text-100 mt-1\"\u003eFat Loss and Metabolic Enhancement\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eGrowth hormone exerts profound effects on lipid metabolism, with fat mobilization and oxidation representing among its most prominent metabolic actions. Research demonstrates that GH stimulates lipolysis in both visceral and subcutaneous adipose tissue by increasing hormone-sensitive lipase activity, resulting in elevated plasma free fatty acid levels. Studies show that a 4-fold increase in plasma GH produces a shift in fuel selection, with 29% more fat oxidation and 69% less carbohydrate oxidation, indicating enhanced metabolic flexibility.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe mechanism involves GH directly binding to receptors on adipocytes, stimulating triglyceride breakdown while suppressing the tissue's ability to accumulate circulating lipids. This creates a net reduction in adipose tissue mass through both decreased lipid synthesis and increased mobilization for oxidation. Research confirms that GH enhances mitochondrial oxidative capacity in skeletal muscle, with 16-35% increases in ATP production rate and citrate synthase activity, directly supporting the tissue's ability to utilize mobilized fatty acids as fuel.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe combination of CJC-1295 and Ipamorelin provides sustained elevation of growth hormone and IGF-1 levels, creating an optimal metabolic environment for body recomposition. The synergistic GH stimulation promotes preferential fat loss while preserving or even enhancing lean muscle mass, a critical distinction from simple caloric restriction which typically results in loss of both fat and muscle tissue. Studies indicate that GH's effects on metabolism include enhanced insulin sensitivity in the context of increased lipolysis, creating favorable conditions for improved body composition.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eImportantly, the selective nature of Ipamorelin ensures that cortisol levels remain unaffected, avoiding the counter-productive effects of elevated stress hormones on body composition. The physiological pulsatile GH pattern produced by this combination maintains receptor sensitivity and prevents the metabolic complications associated with continuous GH elevation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc space-y-2.5 pl-7\"\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eShort KR, et al. \"Enhancement of Muscle Mitochondrial Function by Growth Hormone.\" Journal of Clinical Endocrinology \u0026amp; Metabolism. 2008;93(2):597-604.\u003cspan\u003e \u003c\/span\u003e\u003ca class=\"underline\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/18000087\/\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/18000087\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eGoodman HM. \"Growth hormone and the metabolism of carbohydrate and lipid in adipose tissue.\" Annals of the New York Academy of Sciences. 1968.\u003cspan\u003e \u003c\/span\u003e\u003ca class=\"underline\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK218167\/\"\u003ehttps:\/\/www.ncbi.nlm.nih.gov\/books\/NBK218167\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eJohansen PB, et al. \"Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.\" Growth Hormone \u0026amp; IGF Research. 1999;9(2):106-113.\u003cspan\u003e \u003c\/span\u003e\u003ca class=\"underline\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10373343\/\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/10373343\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"font-claude-response-body-bold text-text-100 mt-1\"\u003eTissue Repair and Recovery Enhancement\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe elevated IGF-1 levels resulting from enhanced GH secretion play crucial roles in tissue repair and recovery processes. Insulin-like growth factor-1 demonstrates significant wound healing and tissue regeneration properties through multiple mechanisms. Research shows that IGF-1 promotes keratinocyte migration and proliferation, accelerates re-epithelialization, enhances collagen deposition, and stimulates angiogenesis in healing tissues.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eStudies demonstrate that systemic IGF-1 administration results in approximately 60% increases in tissue strength during healing of collagenous extracellular matrices. The mechanisms involve IGF-1-mediated stimulation of cellular proliferation, enhanced protein synthesis, and activation of anti-inflammatory pathways. Research indicates that IGF-1 inhibits inflammation and accelerates angiogenesis through Ras\/PI3K\/IKK\/NF-κB signaling pathways, creating an optimal environment for tissue repair.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eIn skeletal muscle, IGF-1 promotes repair through increased satellite cell activation and muscle fiber regeneration. The growth hormone and IGF-1 axis supports recovery from exercise-induced muscle damage by enhancing protein synthesis, reducing inflammation, and improving nutrient delivery through increased vascularization. Clinical observations suggest that the combination of growth hormone secretagogues accelerates recovery time between training sessions and reduces the duration of muscle soreness following intense physical activity.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe synergistic GH stimulation from CJC-1295 and Ipamorelin provides sustained elevation of both GH and IGF-1, creating consistent support for ongoing repair and recovery processes. Research demonstrates that systemic IGF-1 improves healing across various tissue types including skin, ligaments, tendons, and muscle tissue. The preserved pulsatile GH pattern maintains physiological signaling that optimizes tissue repair without the complications associated with continuous hormone elevation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc space-y-2.5 pl-7\"\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eProvenzano PP, et al. \"Systemic administration of IGF-I enhances healing in collagenous extracellular matrices: evaluation of loaded and unloaded ligaments.\" BMC Physiology. 2007;7:2.\u003cspan\u003e \u003c\/span\u003e\u003ca class=\"underline\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC1851714\/\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC1851714\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eGaroufalia Z, et al. \"Insulin-like growth factor-I and wound healing, a potential answer to non-healing wounds: A systematic review of the literature and future perspectives.\" International Journal of Lower Extremity Wounds. 2021.\u003cspan\u003e \u003c\/span\u003e\u003ca class=\"underline\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8212444\/\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8212444\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eWei M, et al. \"IGF-1 inhibits inflammation and accelerates angiogenesis via Ras\/PI3K\/IKK\/NF-κB signaling pathways to promote wound healing.\" Biomedicine \u0026amp; Pharmacotherapy. 2024.\u003cspan\u003e \u003c\/span\u003e\u003ca class=\"underline\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0928098724001593\"\u003ehttps:\/\/www.sciencedirect.com\/science\/article\/pii\/S0928098724001593\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"font-claude-response-body-bold text-text-100 mt-1\"\u003ePhysical Performance and Exercise Capacity\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe combination of enhanced growth hormone and IGF-1 levels supports improved exercise capacity and physical performance through multiple mechanisms. Research demonstrates that growth hormone increases mitochondrial oxidative capacity in skeletal muscle, with significant elevations in ATP production and citrate synthase activity. These changes in cellular energetics directly support enhanced physical performance by improving the muscle's ability to generate energy during exercise.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eStudies show that GH administration promotes shifts in fuel utilization toward increased fat oxidation and decreased carbohydrate oxidation, which can enhance endurance performance by preserving glycogen stores for high-intensity efforts. The enhanced lipolysis and free fatty acid availability provide alternative fuel sources that support prolonged physical activity. Research indicates that GH also increases abundance of muscle mRNAs encoding mitochondrial proteins from both nuclear and mitochondrial genomes, suggesting comprehensive improvements in oxidative metabolism.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe synergistic effect of combining GHRH and GHRP analogs creates more robust GH pulses that closely mimic natural physiological patterns. Research demonstrates that co-administration of these peptide classes yields synergistic increases in GH secretion and enhanced IGF-1 production, potentially providing superior support for training adaptations compared to either compound alone. The preserved pulsatile pattern is critical as it maintains normal receptor function and cellular responsiveness to GH signaling.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eRecovery between training sessions represents another key benefit, with enhanced GH and IGF-1 levels supporting faster repair of exercise-induced muscle damage, reduced inflammation, and improved adaptation to training stress. The combination's effects on sleep quality through GH's natural circadian rhythm enhancement may further support recovery and performance gains.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc space-y-2.5 pl-7\"\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eShort KR, et al. \"Enhancement of Muscle Mitochondrial Function by Growth Hormone.\" Journal of Clinical Endocrinology \u0026amp; Metabolism. 2008;93(2):597-604.\u003cspan\u003e \u003c\/span\u003e\u003ca class=\"underline\" href=\"https:\/\/academic.oup.com\/jcem\/article-abstract\/93\/2\/597\/2598620\"\u003ehttps:\/\/academic.oup.com\/jcem\/article-abstract\/93\/2\/597\/2598620\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eBowers CY, et al. \"Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.\" Journal of Clinical Endocrinology \u0026amp; Metabolism. 1990;71(4):839-843.\u003cspan\u003e \u003c\/span\u003e\u003ca class=\"underline\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/2108187\/\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/2108187\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eGobburu JVS, et al. \"Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers.\" Pharmaceutical Research. 1999;16(9):1412-1416.\u003cspan\u003e \u003c\/span\u003e\u003ca class=\"underline\" href=\"https:\/\/link.springer.com\/article\/10.1023\/A:1018955126402\"\u003ehttps:\/\/link.springer.com\/article\/10.1023\/A:1018955126402\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"font-claude-response-body-bold text-text-100 mt-1\"\u003eSleep Quality and Circadian Rhythm Support\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eGrowth hormone secretion exhibits strong circadian patterns, with the most intense period of release occurring shortly after the onset of deep sleep. The CJC-1295 and Ipamorelin combination supports optimization of these natural rhythms when administered strategically. Research indicates that GHRH demonstrates hypnotic properties, increasing both the duration and intensity of slow-wave (deep) sleep, which represents the most restorative sleep phase.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eEnhanced GH secretion during sleep supports multiple recovery processes including tissue repair, immune function optimization, and metabolic regulation. Studies show that adequate growth hormone levels are essential for normal sleep architecture, with GH deficiency associated with sleep disturbances and reduced slow-wave sleep duration. Conversely, optimization of GH secretion through peptide administration often results in subjective improvements in sleep quality and morning restoration.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe preserved pulsatile nature of GH release with this peptide combination is particularly important for maintaining normal sleep patterns. Continuous GH elevation can disrupt natural rhythms, while pulsatile secretion that aligns with circadian patterns supports rather than interferes with sleep architecture. Many users report enhanced sleep depth, reduced nighttime awakenings, and improved morning energy levels when using this combination, suggesting beneficial effects on sleep-related recovery processes.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe relationship between sleep quality and daytime physical and cognitive performance creates a positive feedback loop: better sleep supports improved training capacity and recovery, while appropriate training and hormone optimization enhance sleep quality, collectively contributing to overall health and performance optimization.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc space-y-2.5 pl-7\"\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eIonescu M, et al. \"Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.\" Journal of Clinical Endocrinology \u0026amp; Metabolism. 2006;91(12):4792-4797.\u003cspan\u003e \u003c\/span\u003e\u003ca class=\"underline\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17018654\/\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/17018654\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eAlba M, et al. \"Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.\" American Journal of Physiology-Endocrinology and Metabolism. 2006;291(6):E1290-E1294.\u003cspan\u003e \u003c\/span\u003e\u003ca class=\"underline\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16825605\/\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/16825605\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv class=\"research-disclaimer\"\u003e\u003cem\u003e\u003cstrong\u003eDisclaimer:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eThe research articles listed above are for informational purposes only. This product is intended for research use only and not for human or veterinary use.\u003c\/em\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"CHEATCODES","offers":[{"title":"Default Title","offer_id":44286994579571,"sku":null,"price":74.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0681\/2316\/4787\/files\/cjc1295_ipa_10mg.png?v=1775966061"},{"product_id":"igf-1-lr3","title":"IGF-1 LR3","description":"\u003ch3 class=\"font-claude-response-subheading text-text-100 mt-1 -mb-1.5\"\u003eResearch Applications\u003c\/h3\u003e\n\u003ch4 class=\"font-claude-response-body-bold text-text-100 mt-1\"\u003eMuscle Growth and Protein Metabolism\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eIGF-1 LR3 demonstrates significant effects on skeletal muscle protein metabolism and muscle mass preservation. A pivotal 1999 study by Hill et al. investigated the effects of IGF-1 LR3 infusion on protein metabolism in beef heifers undergoing weight loss due to restricted feeding. Results showed that continuous intravenous infusion of IGF-1 LR3 tended to preserve both whole-body protein and skeletal muscle protein during the catabolic state. The peptide markedly reduced plasma concentrations of all measured amino acids and glucose, indicating enhanced cellular uptake. These findings suggest IGF-1 LR3 promotes nitrogen retention and reduces protein breakdown, even during periods of energy restriction.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe mechanisms underlying IGF-1 LR3's anabolic effects involve activation of the PI3K\/Akt\/mTOR signaling pathway, which stimulates ribosomal protein S6 and translation initiation factors downstream of mTORC1, thereby enhancing protein synthesis. Simultaneously, Akt activation suppresses the ubiquitin proteasome system through inhibition of FoxO-mediated transcription of E3 ubiquitin ligases (MAFbx\/Atrogin-1, MuRF1), which are responsible for protein degradation. This dual mechanism—increased synthesis combined with decreased breakdown—results in net protein accretion in muscle tissue.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eIGF-1 LR3 also promotes muscle cell proliferation and differentiation through activation of satellite cells, the resident stem cells of skeletal muscle. These cells normally exist in a quiescent state but become activated following muscle injury or mechanical stimulation, proliferating and fusing with existing muscle fibers to support hypertrophy and repair. IGF-1 LR3 directly stimulates satellite cell activation, proliferation, and fusion, processes essential for muscle regeneration and growth. The peptide enhances the conversion of multipotent stem cells into committed muscle lineage cells, accelerating muscle development and tissue repair.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc space-y-2.5 pl-7\"\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eHill RA, Hunter RA, Lindsay DB, Owens PC. Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers. Domestic Animal Endocrinology. 1999;16(4):219-229.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10370861\/\" class=\"underline\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/10370861\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eSchiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF1-Akt\/PKB pathway: insights from genetic models. Skeletal Muscle. 2011;1:4.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4449334\/\" class=\"underline\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4449334\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eRommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K\/Akt\/mTOR and PI(3)K\/Akt\/GSK3 pathways. Nature Cell Biology. 2001;3:1009-1013.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4449334\/\" class=\"underline\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4449334\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"font-claude-response-body-bold text-text-100 mt-1\"\u003eProtection Against Muscle Damage and Dystrophy\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eIGF-1 LR3 exhibits protective effects against contraction-induced muscle injury, particularly relevant in muscular dystrophy pathophysiology. Gehrig et al. (2008) demonstrated that systemic administration of IGF-1 LR3 to dystrophic mdx mice (a model of Duchenne muscular dystrophy) significantly reduced susceptibility to contraction-mediated damage in extensor digitorum longus, soleus, and diaphragm muscles. Following a protocol of lengthening contractions, muscles from IGF-1 LR3-treated animals exhibited lower force deficits compared to controls, indicating enhanced resistance to mechanical injury.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eNotably, this protective effect occurred through mechanisms independent of changes in muscle oxidative metabolism or fatigue resistance, distinguishing IGF-1 LR3's mechanism from native IGF-1. The protection appears to result from the peptide's ability to bypass inhibitory IGFBP interactions, allowing more effective activation of IGF-1 signaling pathways that enhance sarcolemmal stability and reduce membrane damage during eccentric contractions. Contraction-mediated injury represents a major pathological contributor to progressive muscle degeneration in muscular dystrophy, making therapies that attenuate this type of damage clinically relevant.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eAdditional studies in multiple dystrophic mouse models have confirmed IGF-1 analog benefits in improving muscle function and reducing pathological features. The peptide's muscle-protective properties extend beyond genetic muscle diseases, with potential applications in preventing exercise-induced muscle damage, accelerating recovery from injury, and maintaining muscle mass during periods of disuse or immobilization.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc space-y-2.5 pl-7\"\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eGehrig SM, Ryall JG, Schertzer JD, Lynch GS. Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage. Experimental Physiology. 2008;93(11):1190-1198.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/18567600\/\" class=\"underline\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/18567600\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eLynch GS. The therapeutic potential of IGF-I in skeletal muscle repair. Current Opinion in Pharmacology. 2013.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3732824\/\" class=\"underline\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3732824\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eGehrig SM, van der Poel C, Hoeflich A, et al. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy. Growth Hormone \u0026amp; IGF Research. 2012;22:69-75.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1096637412000196\" class=\"underline\"\u003ehttps:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1096637412000196\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"font-claude-response-body-bold text-text-100 mt-1\"\u003eTendon and Connective Tissue Repair\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eIGF-1 demonstrates potent effects on tendon healing and connective tissue regeneration through multiple mechanisms. Research reveals that IGF-1 facilitates tendon regenerative healing by modulating inflammatory responses, promoting tenocyte proliferation and migration, enhancing collagen production—particularly type I collagen which comprises the primary structural component of tendon tissue—and inducing appropriate cell differentiation during the repair process.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eIn vitro studies demonstrate that IGF-1 significantly increases DNA synthesis and collagen I production in tenocyte cultures. The growth factor stimulates tenocyte proliferation in a dose-dependent manner and maintains cell viability in serum-free conditions when combined with other growth factors. In vivo animal studies confirm these findings, showing that IGF-1 treatment accelerates functional recovery from Achilles tendon injury, improves tendon mechanical properties, and enhances collagen organization and composition in healing ligaments.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eSystematic administration of IGF-1 has been shown to enhance healing in collagenous extracellular matrices. Studies using medial collateral ligament (MCL) injury models demonstrate that IGF-1 treatment improves mechanical properties and promotes more organized collagen architecture during healing. The peptide increases the cross-sectional area of regenerating tendon tissue and promotes a greater expansion of neotendon formation over time. Additionally, IGF-1 supports the differentiation of mesenchymal stem cells toward tenogenic lineages, a critical process for successful tendon regeneration.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe mechanisms underlying IGF-1's tendon repair effects involve activation of the IGF-1 receptor on tenocytes and tendon stem cells, leading to enhanced extracellular matrix synthesis, improved cellular migration to injury sites, and optimized remodeling of repair tissue. These effects make IGF-1 a promising therapeutic approach for tendon injuries, which typically heal slowly and often result in inferior mechanical properties compared to uninjured tissue.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc space-y-2.5 pl-7\"\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eMiescher I, Rieber J, Calcagni M, Buschmann J. In vitro and in vivo effects of IGF-1 delivery strategies on tendon healing: A review. International Journal of Molecular Sciences. 2023;24(3):2370.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9916536\/\" class=\"underline\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9916536\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eWang K, Chen Y, Wu J, et al. Insulin-like growth factor-1 (IGF-1) empowering tendon regenerative therapies. Frontiers in Bioengineering and Biotechnology. 2025.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/www.frontiersin.org\/journals\/bioengineering-and-biotechnology\/articles\/10.3389\/fbioe.2025.1492811\/full\" class=\"underline\"\u003ehttps:\/\/www.frontiersin.org\/journals\/bioengineering-and-biotechnology\/articles\/10.3389\/fbioe.2025.1492811\/full\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eProvenzano PP, Alejandro-Osorio AL, Valhmu WB, et al. Systemic administration of IGF-I enhances healing in collagenous extracellular matrices: evaluation of loaded and unloaded ligaments. Journal of Orthopaedic Research. 2007.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC1851714\/\" class=\"underline\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC1851714\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"font-claude-response-body-bold text-text-100 mt-1\"\u003eGlucose Metabolism and Insulin Sensitivity\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eIGF-1 plays a critical role in glucose homeostasis and insulin sensitivity through both direct and indirect mechanisms. The peptide shares approximately 48% amino acid sequence homology with insulin and binds to insulin receptors, though with lower affinity than insulin itself. More significantly, IGF-1 activates hybrid insulin\/IGF-1 receptors and stimulates glucose transport in skeletal muscle and adipose tissue through mechanisms similar to insulin.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eStudies demonstrate that IGF-1 enhances insulin sensitivity by promoting glucose uptake in peripheral tissues while suppressing hepatic glucose production. The peptide activates the PI3K\/Akt signaling cascade, leading to translocation of GLUT4 glucose transporters to the cell membrane and increased cellular glucose uptake. Additionally, IGF-1 indirectly improves insulin sensitivity by suppressing growth hormone (GH) secretion through negative feedback mechanisms; elevated GH levels promote insulin resistance through direct antagonistic effects on insulin signaling, and IGF-1-mediated GH suppression alleviates this resistance.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eResearch in animal models reveals that central nervous system IGF-1 expression significantly improves glucose tolerance and enhances insulin sensitivity. Mice receiving IGF-1 treatment showed increased serum insulin levels, reduced blood glucose levels, improved glucose tolerance, and enhanced insulin sensitivity. These metabolic improvements occurred alongside increased phosphorylation of insulin receptor substrate and Akt, key signaling molecules in the insulin\/IGF-1 pathway.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eClinical studies support IGF-1's role in metabolic regulation. Low circulating IGF-1 levels are associated with increased risk of insulin resistance, metabolic syndrome, and type 2 diabetes development. Conversely, IGF-1 administration to patients with insulin resistance has demonstrated improvements in glycemic control and enhanced insulin sensitivity. The peptide's glucose-lowering effects partially result from its ability to increase fatty acid oxidation in muscle tissue, reducing free fatty acid flux to the liver and improving insulin's suppression of hepatic glucose output.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc space-y-2.5 pl-7\"\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eClemmons DR. Role of insulin-like growth factor I in maintaining normal glucose homeostasis. Hormone Research. 2004;62(Suppl 1):77-82.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15761237\/\" class=\"underline\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/15761237\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eQiu Z, Wei Y, Song Q, et al. Central IGF1 improves glucose tolerance and insulin sensitivity in mice. Nutrition \u0026amp; Diabetes. 2017.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/www.nature.com\/articles\/s41387-017-0002-0\" class=\"underline\"\u003ehttps:\/\/www.nature.com\/articles\/s41387-017-0002-0\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eAguirre GA, De Ita JR, de la Garza RG, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and metabolic syndrome. Journal of Translational Medicine. 2016;14:3.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/link.springer.com\/article\/10.1186\/s12967-015-0762-z\" class=\"underline\"\u003ehttps:\/\/link.springer.com\/article\/10.1186\/s12967-015-0762-z\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eClemmons DR. Metabolic actions of IGF-I in normal physiology and diabetes. Endocrinology and Metabolism Clinics. 2012.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3374394\/\" class=\"underline\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3374394\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"font-claude-response-body-bold text-text-100 mt-1\"\u003eCellular Proliferation and Tissue Development\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eIGF-1 LR3 functions as a potent stimulus for cellular proliferation across multiple tissue types through its activation of IGF-1 receptors and downstream signaling pathways. The peptide's primary mitogenic actions involve stimulation of the MAPK\/ERK pathway, which promotes cell cycle progression, and the PI3K\/Akt pathway, which enhances cell survival and prevents apoptosis. These coordinated effects accelerate cell division rates and support tissue development and regeneration.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eResearch demonstrates that IGF-1 LR3 exhibits superior cell proliferation activity compared to native IGF-1 when tested in cell culture systems. The peptide's reduced binding to IGFBPs allows greater bioavailability and more sustained receptor activation, making it particularly effective for accelerating cell growth in laboratory applications. Studies in mammalian cell culture reveal that supplementation with IGF-1 LR3 at concentrations significantly lower than standard insulin or native IGF-1 results in enhanced cell productivity and proliferation rates.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe peptide influences multiple cell types essential for tissue repair and regeneration. In skeletal muscle, IGF-1 LR3 activates satellite cells, promoting their proliferation and differentiation into mature muscle fibers—a process termed hyperplasia (increase in cell number) distinct from hypertrophy (increase in cell size). In connective tissues, the peptide stimulates fibroblast proliferation and extracellular matrix synthesis. In vascular tissues, IGF-1 supports endothelial cell growth and angiogenesis, contributing to improved tissue perfusion during healing.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eAnimal studies demonstrate that IGF-1 LR3 administration increases organ weight through enhanced cellular proliferation. Seven-day continuous infusion of IGF-1 LR3 in guinea pigs significantly increased the fractional weight of adrenals, gut, kidneys, and spleen compared to controls, indicating tissue growth effects. These proliferative actions occur through activation of anabolic signaling pathways that coordinate increased DNA synthesis, enhanced protein production, and accelerated cell division across target tissues.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc space-y-2.5 pl-7\"\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eConlon MA, Tomas FM, Owens PC, et al. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. Journal of Endocrinology. 1995;146(2):247-253.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7561636\/\" class=\"underline\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/7561636\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eAraujo MS, Guastali MD, Paulini F, et al. Molecular and cellular effects of insulin-like growth factor-1 and LongR3-IGF-1 on in vitro maturation of bovine oocytes: comparative study. Growth Hormone \u0026amp; IGF Research. 2020.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37261455\/\" class=\"underline\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/37261455\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eFrancis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology. 1992.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC1137054\/\" class=\"underline\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC1137054\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 class=\"font-claude-response-body-bold text-text-100 mt-1\"\u003eMetabolic Regulation and Fat Metabolism\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eIGF-1 plays important roles in lipid metabolism and energy homeostasis through effects on both fat storage and utilization. The peptide promotes fatty acid oxidation in skeletal muscle, enhancing the utilization of lipids as an energy source while sparing glucose for other metabolic processes. This metabolic flexibility—the capacity to efficiently switch between carbohydrate and fat oxidation—represents a key component of healthy metabolism.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eResearch demonstrates that IGF-1 stimulates fatty acid uptake and β-oxidation in muscle tissue through multiple mechanisms. The peptide activates AMP-activated protein kinase (AMPK), a central regulator of cellular energy metabolism that promotes fatty acid oxidation while inhibiting lipid synthesis. Additionally, IGF-1 enhances expression and activity of enzymes involved in fatty acid metabolism, including carnitine palmitoyltransferase-1, the rate-limiting enzyme for fatty acid entry into mitochondria for oxidation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eThe peptide's effects on fat metabolism also involve its insulin-like actions. IGF-1 stimulates glucose and amino acid transport into cells, particularly muscle tissue, promoting anabolic processes while reducing substrate availability for fat storage. This nutrient partitioning effect directs dietary nutrients toward muscle protein synthesis and away from adipose tissue storage. Animal studies demonstrate that IGF-1 treatment reduces circulating free fatty acid levels, potentially through increased muscle uptake and oxidation combined with reduced adipose tissue lipolysis.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eIGF-1's metabolic effects extend to whole-body energy balance through its regulation of growth hormone secretion. Elevated GH levels promote lipolysis and increase circulating fatty acids, effects that can contribute to insulin resistance. IGF-1's suppression of GH secretion through negative feedback indirectly improves metabolic function by reducing GH-mediated lipolysis and its associated insulin-antagonistic effects. This complex interplay between IGF-1, GH, and insulin coordinates metabolic regulation across fed and fasted states.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003eStudies in metabolic syndrome and obesity models show that low IGF-1 levels correlate with dysregulated lipid metabolism, increased visceral adiposity, and impaired insulin sensitivity. Restoration of IGF-1 through administration or increased endogenous production has demonstrated improvements in lipid profiles, reduced adipose tissue accumulation, and enhanced metabolic health markers.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body whitespace-normal break-words\"\u003e\u003cstrong\u003eSources:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"[\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc space-y-2.5 pl-7\"\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eAguirre GA, De Ita JR, de la Garza RG, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and metabolic syndrome. Journal of Translational Medicine. 2016;14:3.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/link.springer.com\/article\/10.1186\/s12967-015-0762-z\" class=\"underline\"\u003ehttps:\/\/link.springer.com\/article\/10.1186\/s12967-015-0762-z\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eClemmons DR. Metabolic actions of IGF-I in normal physiology and diabetes. Endocrinology and Metabolism Clinics. 2012.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3374394\/\" class=\"underline\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3374394\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli class=\"whitespace-normal break-words\"\u003eYakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proceedings of the National Academy of Sciences. 1999.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4449334\/\" class=\"underline\"\u003ehttps:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4449334\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv class=\"research-disclaimer\"\u003e\u003cem\u003e\u003cstrong\u003eDisclaimer:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eThe research articles listed above are for informational purposes only. This product is intended for research use only and not for human or veterinary use.\u003c\/em\u003e\u003c\/div\u003e","brand":"CHEATCODES","offers":[{"title":"Default Title","offer_id":44287003623539,"sku":null,"price":69.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0681\/2316\/4787\/files\/IGF-1_LR3.jpg?v=1775966034"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0681\/2316\/4787\/collections\/stacks_img.jpg?v=1776868536","url":"https:\/\/cheatcodespeptides.com\/collections\/peptide-stacks.oembed","provider":"CHEATCODES","version":"1.0","type":"link"}